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ABSTRACT 
Background Although there have been recent advances, cardiovascular disease 
remains the commonest cause of premature death in the United Kingdom. There is a 
need to develop safe non-invasive techniques to aid the diagnosis and treatment of 
patients with cardiovascular disease. 
Objectives The aims of this thesis are: (i) to establish whether coronary artery 
calcification can be measured reproducibly by helical computed tomography; (ii) to 
establish the effect of lipid lowering therapy on the progression of coronary 
calcification; (iii) to determine whether multidetector computed tomography can 
predict graft patency in patients who have undergone coronary artery bypass grafting; 
and (iv), to investigate the role of magnetic resonance imaging to assess plaque 
characteristics following acute carotid plaque rupture. 
Methods In 16 patients, coronary artery calcification was assessed twice within 4 
weeks by helical computed tomography. As part of a randomised controlled trial, 
patients received atorvastatin 80 mg daily or matching placebo, and had coronary 
calcification assessed annually. F ifty patients with previous coronary artery bypass 
surgery who were listed for diagnostic coronary angiography underwent contrast 
enhanced computed tomography angiography using a 16-slice multidetector computed 
tomography scanner. Finally, 15 patients with recent symptoms and signs of an acute 
transient ischaemic attack, amaurosis fugax or su·oke underwent magnetic resonance 
angiography of the carotid arteries using dedicated surface coils. Plaque volume, 
regional plaque densities and neovascularisation were determined before and after 
gadolinium enhancement. 
Results Quantification of coronary artery calcification demonstrated good 
reproducibility in patients with scores > 100 AU. Despite reducing systemic 
inflammation and halving serum low-density lipoprotein cholesterol concentrations, 
atorvastatin therapy did not affect the rate of progression of coronary artery 
calcification. Computed tomography angiography was found to be highly specific for 
the detection of graft patency. Assessment of plaque characteristics by magnetic 
resonance scanning in patients with recent acute carotid plaque was feasible and 
reproducible. 
Conclusions Coronary artery calcium scores can be determined in a reproducible 
manner. Although they corre late wel l with the presence of atherosclerosis and predict 
future coronary risk. there is little role for monitoring progression of coronary artery 
calcification in order to assess the response to lipid lowering therapy. Computed 
tomography can be used reliably to predict graft patency in patients who have 
undergone coronary artery bypass grafting, and is an acceptable non-invasive 
alternative to invasive coronary angiography. Magnetic resonance imaging techniques 
' can be employed in a feasible, timely and reproduc ible manner to detect plaque 
characteristics associated with acute atherothrombotic disease. 
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Although there have been recent advances in diagnosis and treatment, cardiovascular 
disease is the commonest cause of premature death in the United. Coronary heart disease 
(CHD) accounts for over 64, 000 deaths in men and 33,000 deaths in women in the UK 
annually (WHO mortality statistics 2002) which equates to over 22% of all deaths in men 
and 17% in women. Cerebrovascular disease accounts for over 25,500 deaths in men and 
nearly 42,000 deaths in women each year (WHO mortality statistics). Overall, di seases 
directly attributable to arterial disease accounted for 3 1% of all deaths in the UK in 2002. 
The principal initiating event in the pathogenesis of acute cardiovascular events is rupture 
or erosion of the atherosclerotic plaque (Davies 2000). This leads to intravascular 
thrombus formation and the potential for acute vessel occlusion or thromboembolism. 
Clinically, this is most dramatical ly manifest by the onset of acute myocardial infarction 
or stroke. 
1.2 ATHEROSCLEROSIS 
1.2.1 Natural History 
Atherosclerotic lesions occur predominantly in medium-sized muscular arteries, 
including coronary, renal, carotid, basilar, and vertebral arteries. Such lesions are 
categorized according to histological characteristics (Table l. l ; AHA recommended 
classification of atherosclerotic plaque, Fig. l.l (Stary, Chandler et al. 1995)). 
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Table 1.1 AHA recommended classification of atherosclerotic plaque (Stary, Chandler et 
al. 1995). 
Nomenclature and Main Earliest Clinical 
main histology Sequences in progression growth onset corre-mechanism lation 
Type I (initial) lesion 
isolated macrophage I 
foam cells from 
first 
Type II (fatty streak) lesion decade clinically mainly intracellular n growth 
lipid accumulation mainly silent 
Type ro (intermediate) lesion 
by 
lipid 
Type II changes & small Ill accumu-
extracellular lipid pools lation from 
Type JV (atheroma) lesion 
third 
decade 
Type II changes & core of IV 
extracellular lipid 
Type V (fibroatheroma) lesion ~ accelerated 
lipid core & fibrotic layer, smooth clinically 
or multiple lipid cores & fibrotic v .L muscle silent and layers, or malnly calcific, ?OIIagen from or or mainly fibrotic mcrease fourth overt 
decade 







Fig. 1.1 Plaque types (Stary, Chandler et al. 1995). 
The disease process is one which begins in childhood, with an increase in the numbers of 
intimal macrophages and macrophage foam cells (Type I lesion). This progresses to the 
development of fatty streaks (Type II lesions), which have predominantly intracellular 
lipid collections. From the third decade, isolated extracellular lipid pools begin to appear 
(Type III lesions). Type 1-111 lesions are small and do not result in any clinical 
manifestations, nor do they cause any luminal narrowing. 
Lesions in highly susceptible sites of the vascular tree exhi bit higher macrophage 
numbers, a greater lipid content, and have an increased propensity towards progression. 
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These susceptible sites occur throughout the coronary circulation, renal arteries and 
internal carotid artery at the level of the carotid sinus, and are the result of altered 
mechanical stress, primari ly at branching points. These altered mechanics lead to a 
process known as adaptive intimal thickening, whereby the artery adj usts its inner 
contour through localized changes in the thickness of the intima in an attempt to maintain 
normal conditions of flow. As early changes evolve, the lipid pools increase in size to 
form a confluent lipid core (Type IV lesion). Type IV lesions rarely cause any significant 
luminal obstruction unless blood lipid levels are very hjgh, leading to a rapid 
accumulation of lipid in the core. At this stage, the tissue layer between the lipid core 
and the endothelium is recogn.isable histologically as normal intima. As tissue is 
djsrupted by lipid accumulation, smooth muscle cells hypertrophy and collagen is laid 
down to form the fibrous cap, which is characteristic of type V lesions. This fibrous 
connective tissue formation is a reparative response to the injury caused by the disruption 
of normal intercellular matrix by extracellular lipid deposition. The formation of new 
layers initially results in expansion of the vessel wall in order to maintain adequate lumen 
area (Giagov, Weisenberg et al. 1987). Capillaries at the periphery of the lipid core may 
be large and numerous, and this capi llary network may extend into the newly formed 
fibromuscular cap. The extent of such neovasculature is thought to correlate with plaque 
vulnerability (Kerwin, Hooker et al. 2003). Type V lesions may have differing 
compositions, and a subclassification represents these variations. Type Va lesions are 
known as multilayered atheroma, with several lipid cores interspersed with layers of 
fibrous connective tissue. These may result from alterations in vascular haemodynamics 
caused by lumjnal narrowing and also by disruption of l.esion surface with fibrosis of 
5 
resultant haematoma and thrombi deposits. Type Vb lesions contain calcium deposits, 
and in type Vc lesions, fibrosis predominates with a relative paucity of lipid. Type VI 
lesions are a result of surface disruptions, haematoma or thrombosis superimposed upon a 
type IV or V lesion. These lesions are termed complicated Lesions and are subclassified 
into Type VIa, surface disruption , Type Vlb, haematoma or haemorrhage, and Type VIc, 
thrombosis. 
1.2.2 Calcium Deposits in Atherosclerotic Lesions 
Type I-II lesions develop during childhood and puberty, and are composed of lipid-laden 
macrophages and, later, lipid pools. As the lipid core expands, replacing the intima, 
calcium granules appear in the cytoplasm of smooth muscle cells. As these cells 
apoptose and break up, the calcium becomes extracellular and forms aggregates, which 
are di stributed throughout the lipid core. Calcification of cell components also occurs 
fo llowing apoptosis, further contributing to calcium load. As plaques progress, typically 
around the fifth decade of life, calcific deposits can become confluent, with fusion of 
adjacent aggregates to form lumps or plates of calcium. It has been suggested that 
arterial calcification may represent an attempt to stabilize the atherosclerotic 
endothelium, by forming a protective layer. [ntravscular ultrasound (IVUS) studies have 
shown that calcified lesions are relatively more stable than their non-calcified 
counterparts (Mintz, Popma et al. 1 995). Indeed, a plaque with a heavily calcified cap is 
around five times stiffer than a non-calcified lesion, and resi stant to rupture (Lee, 
Grodzinsky et al. 1991 ). However, the interface between a calcified section and a non-
calcified section can be a site prone to rupture, particularly in the context of post-
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angioplasty dissection, due to increased stress near the junction of the calcific plaque and 
the adjacent intima. It is thought, however, that with time and more extensive 
calcification, these weak points become less vu lnerable, which would explain why, in 
general, calcification is not thought to be an indicator of a p laque which is at high risk of 
rupture. 
1.2.3 Vulnerable Plaque 
Although luminal narrowing by atherosclerotic plaques is responsible for some of the 
clinical manifestations of the disease, it is plaque disruption and subsequent occlusive 
thrombus formation that causes the most serious acute clinical manifestations, namely 
acute ischaemic symptoms of stroke, myocardial infarction and sudden death. 
Observational studies have shown that the majority of cu lprit lesions have <70%, and 
often <50%, luminal stenosis (Giroud, Li et al. 1992). The reason being that, in addition 
to plaque morphology, positive versus negative remodeling has an important role to play 
in determining the overall effect on lumen size. The greater outward remodeling, first 
described by Glagov et at (Glagov, Weisenberg et at. 1987), of unstable or vulnerable 
plaques may minimize luminal compromise despite large plaque volume. IVUS studies 
support this and have shown a correlation between outward, or positive remodeling and 
unstable clinical presentation, whereas inward, or negative remodeling is more common 
in stable angina (Schoenhagen, Ziada et al. 2000). 
Rupture-prone plaques have been shown to have different histomorphological features to 
stable intact plaques. So called vulnerable plaques tend to be large, exhibiting positive 
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remodeling, with a large lipid core (occupying more than 40% of the plaque volume), a 
thin fibrous cap which is depleted of smooth muscle cells and collagen and therefore 
easily disrupted or fissured. In addition, they are characteristically accompanied by 
numerous macrophages and inflammatory cells at the cap surface (Libby 2001). The 
smooth muscle cell population also has a bearing on plaque stability, and sites of plaque 
rupture leading to fatal occlusive thromboses typically have few smooth muscle cells 
(Davies, Richardson et al. 1993). The structural component of the fibrous cap includes 
collagen, elastin and proteoglycans which are derived from smooth muscle cells. The cap 
forms a protective barrier between the circulating blood and the highly thrombogenic 
lipid core, but this thins out in the vicinity of the rupture. Vulnerable plaques frequently 
show increased neovascularity (Tenaglia, Peters et al. 1998) which may provide a source 
for recruitment of inflammatory cells into the plaque. 
lnflammatory cytokine dynamics also have a major bearing on plaque stabil ity. 
Depletion of matrix components from the fibrous plaque leads to cap thinning and 
predisposes the cap to rupture, either spontaneously or in response to haemodynamic or 
other triggers. Enhanced matrix breakdown has been attributed to a family of matrix-
degrading metalloproteinases (MMPs) that are expressed by inflammatory cells (Brown, 
Hibbs et al. 1995; Rajavashisth, Xu et al. 1999) and activated by inflammatory cytokines, 
reactive oxygen species and haemodynamic stress, all of which are components existing 
in the atherosclerotic plaque and its surrounding environment (Rajavashi sth, Xu et al. 
1999). 
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1.3 DIAGNOSTIC CHALLENGES 
With advances in technology, techniques for identification and quantification of 
atherosclerotic plaque disease have improved immeasurably over the past decade. In 
addition, improved pharmaceutical interventions with which to aid the prevention, and 
reduce progression, of atherosclerotic disease has placed even more emphasis on 
identifying 'at-risk' patients. Catheter-based procedures give some information as to the 
morphological and haemodynamic characteristics of atherosclerotic plaque, but image 
only the lumen and carry the risk of an invasive procedure. There is a need to develop 
techniques with which to image vessels non-invasively both to aid diagnosis and 
treatment, and to minimise risks associated with invasive imaging such as coronary 
angiography. Non invasive imaging techniques provide the opportunity to detect lesions 
before symptoms occur, to detect so called vulnerable plaques and, potentially, to 
monitor disease progression. 
1.3.1 Computed Tomography 
Computed tomography (CT) was invented in 1972 by the British engineer Godfrey 
Newbold Hounsfield at THORN EMI Central Research Laboratories, and independently 
by Allan McLeod Cormack of Tufts University, Massachusetts. The idea was conceived 
in 1967, and publicly announced in 1972. In 1979, they were jointly awarded the Nobel 
Prize for Medicine, and Hounsfield later honoured with Knighthood in England for his 
contributions to medicine and science. 
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The original prototype took 160 paraJiel datasets through 180 angles, each 1° apart. The 
scan duration was over five minutes, and the processing time a further two and a half 
hours by algebraic reconstruction techniques. The first clinical scanners became 
available between 1974 and 1976 and were limited to imaging of the brain only. The 
scanner involved the use of a water filled Perspex tank with a pre-shaped rubber head 
piece which enclosed the patient's head, in order to reduce the dynamic range of the 
radiation reaching the detectors. The resolution of early scanners was relatively low, 
having a matrix of only 80 x 80 pixels. Whole body systems, however, soon became 
available and were widely used in clinical practice by 1980. 
First generation scanners used a single pencil beam of radiation and a single detector. 
The fixed source/detector gantry worked on a translate-rotate basis, rotating in 1° 
increments and taking a total of 3-5 minutes for a sing le slice. Second generation 
scanners used a narrow fan shaped x-ray beam falling on a small curved array o f 
detectors, allowing the translation and rotation to be increased to 30°, thereby requiring 
fewer angular steps and reducing the scan time to around 20 seconds per slice. Third 
generation scanners were faster again, with a wider fan shaped beam of x-rays being 
directed towards an array of detectors that are in a fixed position relative to the x-ray 
source. This e liminated the need for the time consuming translation phase by s imply 
rotating continuously through 360° round the patient. This reduced the scan time to I 0 
seconds per slice, thereby making imaging of, for example, chest or abdomen practicable, 
where it had previously been limited to the head. In fourth generation scanners, the x-ray 
tube alone rotates round the patients who is positioned in a stationary 360° ring of 
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detectors and is equivalent to third generation scanners in terms of speed of scanning. 
The use of slip-ring technology bas replaced the spooled cable technology of older CT 
scanners, allowing indefinite rotation of the tube, making possible helical scanning. 
Further increase in scan speed is possible by use of multidetector row CT systems 
(MDCT), whereby multiple stationary detector rings allow multiple slices to be scanned 
simultaneously. MDCT permits reconstruction of images in planes other than axial, and 
has made possible the recent advances in cardiac imaging and CT angiography. 
CT offers the potential to provide high definition images of the heart and has the benefit 
of being non-invasive. Electron-beam CT (EBCT) has been developed and used almost 
exclusively for imaging the heart, due to its high temporal resolution which is required to 
minimise movement artefact associated with the beating heart. EBCT employs a rapidly 
rotating electron beam which is focussed on a stationary tungsten target, producing 
temporal resolution of 50-100 ms. The majority of published cardiac imaging data has 
been performed using EBCT, but recent technological advances in MDCT have enabled 
the simultaneous acquisition of multiple overlapping sections per gantry rotation. This, 
in addition to increased gantry rotation speed, has resulted in high temporal and spatial 
resolution cardiac imaging in a single breath hold (Fuchs, Kachelriess et al. 2000). While 
EBCT has, until recently, had the advantage of better temporal resolution, MDCT offers a 
higher signal-to-noise ratio, shorter scan time and higher spatial resolution. 
II 
1.3.2 Magnetic Resonance Imaging 
Felix Bloch, from Stanford University, and Edward Purcell, from Harvard University 
discovered the magnetic resonance phenomenon independently in 1946. They were 
jointly awarded the Nobel prize for physics for their discovery in 1952. Between 1950 
and 1970, it was developed and used for chemical and physical molecular analysis. In 
1971, Raymond Damadian, a medical doctor at the State University of New York in 
Brooklyn, showed that the nuclear magnetic relaxation times of tissues and tumours 
differed, leading to the idea that the technique may be used as a means of detecting 
cancer. Magnetic resonance imaging (MRI) was first demonstrated on small test tube 
samples in 1973 by Paul Lauterbur, a Professor of Chemistry at the State University of 
New York at Stony Brook, and described in the seminal paper entitled 'Image formation 
by induced local interaction; examples employing magnetic resonance', published in 
Nature (LAUTERBUR 1973). Lauterbur described a new imaging technique which he 
termed zeugmatography, referring to the joining together of a weak gradient magnetic 
field with the stronger main magnetic field allowing the spatial localisation of two test 
tubes of water. He used a back projection method to produce an image of the two test 
tubes. In 1975, Richard Ernst, from Zurich, proposed magnetic resonance imaging using 
phase and frequency encoding and the Fourier Transform which provides the basis of 
current MRI techniques. Peter Mansfield, who led a nuclear magnetic resonance research 
group in Nottingham, further developed the utilisation of gradients in the magnetic fie ld, 
and demonstrated mathematical analysis of the signals in order to develop a useful 
imaging technique. In 2003, the Nobel Prize for Physiology and Medicine was awarded 
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to Paul Lauterbur and Peter Mansfield for their discoveries concerning magnetic 
resonance imaging. 
The first commercial scanner in Europe was installed in 1983 in the Department of 
Diagnostic Radiology at the University of Manchester Medical School. Since then, 
further applications have been developed, including echo-planar imaging, used to 
perform real-time movie imaging of a single cardiac cycle, magnetic resonance 
angiography, allowing imaging of flowing blood without the use of contrast agents, and 
functional MRJ (fMRI) which allows mapping of the function of the various regions of 
the human brain. The past twenty years have seen MR1 become a widely used diagnostic 
imaging technology and, with new techniques and ever more powerful machines 
emerging, the speed and precision of MRI has increased dramatically. It is likely to 
supersede conventional catheter angiography as the imaging modality of choice in 
vascular disease, and provides a highly flexible non-invasive alternative in vascular and 
cardiac imaging as well as offering information on function. 
Magnetic resonance imaging is based upon the radiofrequency signal from protons 
followi ng the administration of a radiofrequency pulse. The emi tted signal varies as to 
the water content and relaxation times (Tl and T2), with signal intensities on an MR 
image reflecting the biochemical environment of protons in the tissue of interest. 
Experimental evidence has shown that MRI may be a useful tool for imaging both native 
coronary arteries and bypass graft vessels. However, this is technically demanding due to 
the small size of the vessels, their complex three dimensional anatomy and their constant 
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motion due to cardiac and respiratory variation. MR is used with greater success for 
evaluation of the peripheral vasculature. In addition to detecting stenosis or occlusion of 
an artery, MRI can be used to assess the vessel wall directly for atherosclerotic changes 
and, by way of plaque characterisation, may help identify patients at high risk of cardiac 
events. 
1.4 THERAPEUTIC STRATEGIES 
The association between raised plasma cholesterol and cardiovascul.ar risk is well-
establi shed. Statin therapy has a proven role in the primary (Shepherd, Cobbe et al. 1995; 
Downs, Clearfield et al. 1998) and secondary (4S trial investigators, 1994; LIPID trial 
investigators, 1998; Lewis, Moye et al. 1998; Heart Protection Study trial investigators, 
2002) prevention of cardiovascular disease. The 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) reductase inhibitors (statins) are the most potent class of drugs available 
for the treatment of hypercholesterolaemia, accounting for 96% of all drugs used in the 
treatment of this condition. The beneficial effect of lipid-lowering upon morbidity and 
mortal ity in high ri sk subjects in WOSCOPS (40 mg pravastatin) (Shepherd, Cobbe et al. 
1995) as well as those with established coronary artery disease is validated in large 
population-based studies including 4S (using 20-40 mg simvastatin), CARE and LIPID 
(both using 40 mg pravastatin) (4S trial investigators, 1994; LIPID trial investigators, 
1998; Lewis, Moye et al. 1998) where 25-35% reductions in LDL-cholesteroi led to 24-
37% fewer fatal and non-fatal myocardial infarctions. The Heart Protection Study (HPS) 
showed that even patient populations with low serum cholesterol concentrations (35% 
with no previous coronary disease) benefited from statin therapy (simvastatin 40 mg) 
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with a reduction in cardiovascular mortality of 17% and in all vascular events of 24% 
(Heart Protection Study Investigators, 2002). A recent meta-analysis of 14 randomised 
trials of statins showed that an overall reduction of around one fifth per rnmol/L LDL 
cholesterol reduction equated to a reduction by 48 per 1000 major cardiovascular events 
in those with pre-existing CHD, and 25 per 1000 amongst those with no disease at 
baseline (Baigent, Keech et al. 2005). The mechanisms whereby lipid-lowering might act 
beneficially include atheromatous plaque regression and stabiUsation (Jukema, Bruschke 
et al. 1995; Rosenson and Tangney 1998) and attenuation of coronary endothelial 
dysfunction (Treasure, Klein et al. 1995). Statins may also directly modify 
atherosclerosis independent of cholesterol lowering effects through additional pleiotropic 
effects. 
Despite effective lipid-lowering therapy in several primary and secondary prevention 
trials with statins, most patients continue to experience coronary and cerebrovascular 
events. The PROVE-IT trial demonstrated that patients who achieve a reduction in LDL-
cholesterol to <70 mg/dl and hsCRP <2mg/l have the lowest rates of recurrent myocardial 
infarction and cardiovascular death amongst statio-treated patients. However, the study 
also demonstrated that current aggressive lipid-lowering regimens (atorvastatin 80 mg), 
whilst achieving superior reduction in LDL-cholesterol, were not sufficient to bring the 
majority of patients to below the threshold required to maximise benefit (Ridker, Morrow 
et al. 2005). The Treating New Targets study (TNT) demonstrated that aggressive lipid-
lowering with atorvastatin 80 mg was associated with a reduction in cardiovascular 
events compared with standard LDL-cholesterol lowering in patients with acute coronary 
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syndrome, but at the expense of an increased incidence of adverse drug reactions 
(LaRosa, Grundy et aJ. 2005). 
Clinical and basic experimental studies suggest that aggressive lipid-lowering may also 
improve acute and long-term clinical outcomes by acti ng to stabili se plaque and inducing 
plaque regression, ultimately decreasing total plaque burden. In the Atorvastatin Versus 
Revascularisation Treatment (A VERT) study, a randomised study investigating 
aggressive lipid lowering versus intervention, 341 patients with stable single vessel 
disease who received 80 mg of atorvastatin to achieve a mean serum LDL-cholesterol of 
2.0 mmol/1 had a lower incidence of combined ischaemic events compared to treatment 
with coro nary angioplasty.(Pitt, Waters et al. 1999) This study suggested that aggressive 
reduction in lipid levels is more likely to prevent further progression of minimal coronary 
artery lesions than angioplasty by helping to stabilise atherosclerotic plaques, thereby 
preventing plaque rupture and reducing the incidence of ischaemic events. 
Experimental models suggest that statins foster plaque stability through a reduction in 
macrophage cholesterol ester content and increased smooth muscle cell proliferation and 
collagen production. The thrombotic sequelae of plaque disruption are mitigated by 
statins through inhibition of platelet aggregation and maintenance of a favourable balance 
between pro-thrombotic and fibrinolytic mechanisms (Takemoto and Liao 200 I). Statins 
reduce progression of atheromatous plaque and new lesion formation in subjects with 
e levated LDL-cholesterol (Multicentre Atheroma Study (MAAS) 1994; Jukema, 
Bruschke et al. 1995; Pitt, Mancini et aJ. 1995). In the coronary circulation, the Reversal 
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of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial compared the 
effect of moderate lipid lowering usi ng 40 mg pravastatin with aggressive lipid lowering 
using 80 mg atorvastatin upon the progression of atheroma. There was a significant 
difference in the primary endpoint of the percentage change in atheroma volume, with an 
increase of 2.7% with pravastatin compared to -0.4% with atorvastatin (p<0.05). An 
additional anti-inflammatory effect has been postulated, and is supported by a greater 
reduction in CRP (36% with atorvastatin compared with 5% with pravastatin) and 
atherogenic lipoproteins in the atorvastatin group (Nissen, Tuzcu et al. 2004). It was not, 
however, powered to examine clinical events. The PROVE-IT (Pravastatin or 
Atorvastatin Evaluation and Infection Therapy) Trial showed that intensive lipid lowering 
with atorvastatin 80 mg reduced the cardiovascular cl inical event rate in patients recently 
hospitalised with acute coronary syndrome when compared with standard Lipid lowering 
with pravastatin 40 mg (Cannon, Braunwald et al. 2004). The benefit emerged as early as 
30 days, and was consistent over time, suggesting that the population of patients with 
acute coronary syndromes, who have a culprit lesion and frequently multiple additional 
vulnerable plaques, can derive particular benefit from early and intensive lipid lowering 
with statins. The current evidence base confirms the benefit of statin therapy irrespective 
of baseline LDL-cholesterol levels and there is a compelling case for aggressive lipid 
lowering in all patients with known vascular disease. 
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1.5 SCREENING AND DIAGNOSTIC TOOLS 
1.5.1 Coronary Artery Calcium Scoring 
The presence of coronary artery calcification is synonymous with atheromatous plaque 
(Frink, Achor et al. 1970; Rifkin, Parisi et al. 1979). Frink eta! originally compared the 
association between coronary artery calcification (CAC) and occlusive coronary artery 
di sease on radiographic and pathologic studies, and showed a correlation between the 
degree of calcification and the presence of significant narrowing (Frink, Achor et al. 
1 970). Since then, there have been numerous studies confirming this association. 
CAC is an independent risk factor for coronary heart disease, with even low coronary 
calcium scores at computed tomography doubling the risk of coronary events.(Pietcher, 
Tice et al. 2004) The extent of arterial calcification correlates closely with 
atherosclerotic burden, (Sangiorgi, Rumberger et al. 1998) and a high coronary calcium 
score at computed tomography denotes a very high risk of future coronary events 
(Wayhs, Zelinger et al. 2002). Recently published research has shown that coronary 
calcium score is an accurate predictor of coronary artery events independent of standard 
risk factors (Arad, Goodman et al. 2005). Because CAC is an easi ly detected surrogate 
for atherosclerotic plaque disease, it is a potential tool for predicting cardiac risk. Indeed, 
CAC detection as a way of screening for the presence of asymptomatic coronary artery 
disease and is being used increasingly in centres around the world. 
One method of detecting of coronary calcification is by CT imaging. Previously, 
conventional and spiral CT exhibited poor spatial and temporal resolution, and much of 
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the published research into this modality has used EBCT, a modality which is not readily 
available in routine clinical practice in the UK. EBCT imaging involves acquisition of 
30-40 images over the length of the myocardium, each slice having a fixed thickness of 3 
mm with the entire coronary tree being imaged in a single breath hold (20-30 seconds). 
EBCT has been shown to allow easy quantification of CAC load, but at the expense of 
poor reproducibility (interscan variability between studies varying from 13-38% (Shields, 
Mielke et al. 1995; Callister, Cooi l et al. 1998; Achenbach, Ropers et al. 2001)). Not 
only does this degree of variability devalue the absolute score, it also jeopardises the 
ability to detect any changes in the score over time. However, the latest generation of 
MDCT scanners (16-slice and 64 slice), have improved temporal and spatial resolution. 
This has Jed to improved accuracy and reproducibility, and favourable comparison 
between spiral CT and EBCT (Carr, Crouse et al. 2000; Kopp, Ohnesorge et al. 2002). 
Kopp et al (Kopp, Ohnesorge et al. 2002) demonstrated that, when compared with EBCT, 
MDCT allows accurate and repeatable measurements of CAC to be obtained, with low 
interscan variabi lity. 
Quantification of coronary artery calcium us.ing CT was first described by Agatston et al 
(Agatston, Janowitz et al. 1990) in 1990. A threshold of 130 Hounsfield units (HU) was 
used to denote the presence of calcium, and a coronary calcium score was determined by 
placing a region of interest around all calcified lesions within a coronary artery (Fig 1.2). 
A total score was determined by adding up the scores for each slice. This method has 
been reproduced throughout the literature and the scores have been used as a predictor of 
risk. A metanalysis of relevant articles calculated that a coronary artery calcium score of 
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between I and 100 equates to an adjusted relative ri sk of 2.1 (Pletcher, Tice et al. 2004 ). 
There is evidence to suggest that the coronary calcium score may be used as a predictor 
of ri sk in asymptomatic patients(Pletcher, Tice et al. 2004) but, until recently, little 
conclusive evidence to support its use in monitoring disease progression or response to 
therapy (Arad, Spadaro et al. 2005; Raggi, Davidson et al. 2005). 
Fig. 1.2 SmartscoreTh1, a program used to calculate CAC score by drawing a region of 
interest around all calcified lesions in each coronary artery (GE Healthcare, 
www. geheal thcare.com) 
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1.5.2 Computed Tomography Angiography 
Whilst CAC is indicative of atheroma and may be a useful screening tool, it provides no 
information on stenosis severity hence the need for .invasive imaging modalities. The 
gold standard method of assessing coronary arterial patency is coronary angiography. 
Life-threatening complications are rare (approx. 1 in lOOO), but include MI, stroke, aortic 
or coronary dissection, cardiac rupture, air embolism, arrhythmia and peripheral vascular 
complications such as haemorrhage, infection or limb ischaemia. Other complications 
are more common and include haematoma at puncture site, angina, vasovagal reactions 
and allergies to contrast agents. The assessment of coronary arterial patency in a non-
invasive and readily available manner would have major benefits for the management and 
treatment of patients with coronary artery disease. 
CT angiography (CTA) is a technique which can be performed rapidly and safely for the 
assessment of vascular disease. With the advent of MDCT, excellent image quality is 
now possible with higher resolution than was previously achieved with single detector 
row technology. Cun·ent MDCT scanners obtain up to 16 simultaneous helices, and 64-
slice scanners are now becoming available. CTA has several advantages over 
conventional angiography, the foremost being that it is less invasive. In addition, it 
permits three-dimensional volumetric reconstructions, allowing visualisation of the 
anatomy from multiple angles and in multiple planes after a single acquisition. It also 
allows visualisation of surrounding soft tissues and adjacent anatomic structures, and is 
more cost effective than conventional angiography and traditional methods of 
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investigation such as exercise ECG and stress echo (Biuemke and Chambers 1995; 
Dewey and Hamm 2007). Coronary CTA is typically performed in a spiral scan mode, 
permitting three-dimensional scanning of the heart during a single breath hold. Data are 
retrospectively gated to the electrocardiogram to reconstruct the images during the 
diastolic phase of the cardiac cycle. Reconstruction is possible with s1ice thickness as 
little as 0.75 mm and a spatial resolution of approximately 0.4 x 0.4 mm. Patient 
radiation dose at MDCT is typically in the region of 11.0±1.9 for 16-slice CTA and 
L 1±4.1 mSv for 64-slice CTA (Hausleiter, Meyer et al. 2006). 
Intravascular contrast enhancement is employed in order to differentiate vessel lumen 
from vessel wall at CT. This allows both angiographic evaluation of the coronary artery 
lumen and characterisation of the coronary artery wall. Reconstruction algorithms allow 
the vessels to be displayed at various axes in order to follow the course of individual 
coronary arteries (Fig. 1.3). Technology also permits display of three dimensional 
volume rendered images which, whilst allowing assessment of spatial orientation, provide 
limjted information about the arterial lumen and vessel wall (Fig. 1.4). The sensitivity 
and specificity for detection of significant luminal stenoses (>50%) with the current 16 
slice MDCT, when measures are taken to ensure adequate heart rate control of around 60 
beats per minute, is around 90% (Nieman, Cademartiri et al. 2002; Ropers, Baum et aJ. 
2003; Mollet, Cademartiri et al. 2004). 
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Fig. 1.3 CT coronary angiogram; multi planar reconstruction algorithm 
Fig. 1.4 CT coronary angiogram; Volume rendered image 
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MDCT is a feas ible alternative to invasive coronary angiography in patients with a stable 
heart rhythm and who are able to co-operate with the required 20 second breath hold. 
However, it is of limited value in those with irregular heart rhythms, and atrial fibri llation 
is a contraindication. Frequent extrasystoles may also degrade image quality due to 
interference with ECG gated reconstruction. Rapid heart rates and inadequate breath 
holding during the scan may aJso contribute to motion artefact. Large depositions of 
calcium in the vessel wall interfere with image quality, causing partial voluming and 
beam hardening which can completely obscure the cross section of the vessel and prevent 
assessment of the patency of the coronary artery lumen. Similarly effects, metal objects 
such as stents, surgical clips, and sternal wires can also interfere with assessment of the 
vesseL Finally, even in co-operative patients with stable heart rates, coronary artery 
motion artefacts may still interfere with image quaHty, in particular in the assessment of 
the right coronary artery, the most rapidly moving segment and the site of most motion 
artefacts. 
The large calibre and more static location of bypass grafts make them particularly 
suitable for investigation by potential non-invasive imaging modalities such as MDCT 
angiography. Published data have reported sensitivity and specificity of up to l 00% and 
99.4% respectively for the detection of graft patency in the immediate post-operative 
period (Song, Ito et al. 2005). This study, however, looked at patients immediately post-
coronary artery bypass operation, who may be expected to have a high patency rate and 
no graft vasculopathy, thereby minimising any ambiguity caused by poor flow in 
chronically diseased grafts. Recent studies looking specifically at graft patency outwith 
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the immediate postoperative period have reported sensitivities of 90-100% and 
specificities of 88-100% for detection of graft patency (Achenbach, Moshage et al. 1997; 
Engelmann, von SmekaJ et al. 1997; Hoshi, Yamauchi et al. 2001; Marano, Storto et al. 
2004) and as good as 100% and 97% respectively for the detection of significant stenoses 
(Achenbach, Moshage et al. 1997). 
Whilst there have been many modest studies assessing the ability of CTA to detect vessel 
patency and stenosis, the clinical value of MDCT is yet to be established in large 
multicentre studies, evaluating populations with differing prevalence, presentation and 
extent of coronary arterial disease. Until this is achieved, conventional invasive 
angiography remains the gold standard method of assessing coronary artery disease. 
1.5.3 Magnetic Resonance Angiography 
Acute cardiovascular events, particularly acute coronary syndromes and stroke, are a 
consequence of atherosclerotic plaque rupture. Coronary angiography provides 
information regarding stenosis severity, but not plaque volume or morphology. Luminal 
narrowing is an indirect measure of plaque size and may underestimate the true plaque 
burden. Glagov et al described the phenomenon of compensatory enlargement, whereby 
the coronary arteries enlarge in relation to plaque area such that functionally significant 
luminal stenoses may not be evident until the plaque occupies up to 40% of the internal 
elastic lamina area (Giagov, Weisenberg et al. 1987). In addition, as discussed earlier, 
IVUS studies have shown a correlation between outward, or posi tive remodeling and 
unstable clinical presentation (Schoenhagen, Ziada et al. 2000). This emphasises the 
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importance of imaging modalities which can identify the inner and outer adventitial 
margins. 
High resolution imaging of coronary arteries is currently only possible with invasive 
techniques, such as IVUS (Newby, McLeod et al. 2001; McLeod, Newby et al. 2003). 
IVUS imaging of complex atherosclerotic p laques is limited by the poor resolution of in 
situ thrombus, potential distortion of geometry and the inability to image though calcified 
plaques. Non-invasive techniques, such as MRI, hold promise, but applicability to the 
coronary circulation is limited by the relatively smaJI calibre of the coronary vasculature 
and the movement artefact induced by continuous myocardial contraction. Carotid 
arteries are more suitable for non-invasive imaging because of their greater calibre, 
superficial location and relatively static position. This vessel, therefore, lends itself more 
readily to the assessment of acute plaque events and subsequent remodelling. MRI 
provides a modality of non-invasive imaging without the need for ionising radiation and, 
with the use of dedicated surface coils, can produce high-resolution images of carotid 
atherosclerotic plaques. 
MRI differentiates plaque components based upon differences in their chemical 
composition, water content, physical state, molecular motion of diffusion. It involves 
subjecting the patient to a high local magnetic field which aligns the protons in the body; 
these protons are excited by a radiofrequency pulse and subsequently detected by receiver 
coils. The abili ty to obtain images of the atherosclerotic vessels is dependent upon the 
amount of available signal, contrast and the lack of noise. Using dedicated surface coi ls, 
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images of the carotid artery can be obtained with resolution of 0.4 x 0.4 x 3 mm. The 
images can be 'weighted' to the Tl, T2 or proton density values which emphasises 
different properties and is useful to differentiate between calcium, lipid, fibrous and 
thrombus components. The signal intensities on an MR image reflect the biochemical 
environment of protons in the tissue of interest, allowing tailoring of sequences to 
optimise the visualisation of specific tissue types. It is possible also to acquire three 
dimensional datasets that provide reproducible quantitative tissue information from 
isotropic voxels. MR can also provide contrast between the vessel wall and adjacent 
lumen by using flow-sensitive pulse sequences. Thus, MR can be used to image the 
vessel lumen in terms of flowing blood as well as simultaneously providing tissue 
information that describes the vessel wall (Fig. 1.5). The typical morphology of a 
vulnerable plaque consists of a thin fibrous cap which may be ulcerated or fissured, 
overlying a large necrotic core. The different properties of these components have been 
characterised in terms of their signal intensity characteristics on Tl, T2, and intermediate-
weighted images. 
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Fig. 1.5 Carotid MR angiogram (left) and cross sectional MR black blood images of 
carotid arteries (middle and right) (Fayad and Fuster 200 l ). 
With the help of dedicated software programmes, it is possible to utilise the images 
prov.ided to acquire accurate and reproducible measurements of plaque volume. Yuan et 
al assessed carotid wall area measurements in patients scheduled for carotid 
endarterectomy with high resolution MRI and found that results strongly agreed with ex-
vivo measurements, with high within- and between-reader agreements (Yuan, Beach et 
al. 1998). Cal et al have demonstrated the abi lity of high-resolution multicontrast MRI to 
classify intermediate to advanced atherosclerotic lesions as described in the AHA 
classification (Cai, Hatsukami et al. 2002). Type III lesions, which consist of diffuse or 
eccentric thickening of the vessel wall containing lipid pools, appear as focal areas of 
high signal within the wall on Tl-weighted and PD images. Type IV or V lesions, 
containing Upid or necrotic core, may show high signal intensi ty or iso-signal intensity on 
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Tl-weighted, high or iso-signal intensity on PD weighted, and varied signal intensity on 
T2-weighted images (Cai, Hatsukami et al. 2002). Lumen surface defect and recent 
haemorrhage are detectable by multicontrast MR (Yuan, Mitsumori et al. 2001; Yuan, 
Zhang et al. 2002). Intact fibrous cap is seen as a band of low signal on TOF images, 
with the absence of this band indicating thin or absent cap. Plaque rupture is suspected 
when this high signal band is absent on TOF and a region of high signal intensity is seen 
adjacent to the lumen. Recent haemorrhage is seen as high signal intensity in both Tl 
weighted and TOF images. The calcification seen in type Vll plaque is detectable by the 
presence of irregular low signal intensity on all contrast-weighted images. Type vm 
plaque is highly fibrotic , with Uttle or no lipid core, and is more a diagnosis of exclusion 
when a stenosis is seen without the characteristics which classify plaques as above. 
Digital subtraction MR angiography is currently used in clinical practice in order to 
assess vessel stenosis. However, the information provided from high resolution magnetic 
resonance imaging with dedicated surface coils promises advancing imaging of both the 
carotid artery lumen as well as plaque morphology. This wilJ greatly improve our abiUty 
to identify high risk patients. In addition, it will improve our understanding of plaque 
development, behaviour and its acute consequences as well as aiding in the development 
and targeting of novel therapeutic strategies to prevent progression to cerebral infarction. 
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1.6 AIMS 
1.6.1 Chapter 3 
The long term consequences of vascular disease require tbe provision of substantial 
health care resources. The identifi cation of high ri sk patients is essential for appropriate 
and efficient treatment. Screening tools must be able to produce reli able and 
reproducible data. We aim to establish that, using multidetector computed tomography, 
CAC score can be measured in an acceptably reproducible manner. 
1.6.2 Chapter 4 
Aggressive lipid lowering has a major role in the treatment of established atherosclerotic 
disease. The presence of coronary artery calcification is a surrogate fo r the degree of 
plaque burden. We aim to establi sh the effect of lipid lowering therapy on the 
progression of coronary calcification as assessed by computed tomography. 
1.6.3 Chapter 5 
Coronary artery bypass graft stenosis and occlusion may occur in the earl y post-operative 
period or as a late complication. The assessment of graft patency in a non-invasive and 
readily applicable manner would have major benefits for the management and treatment 
of patients with prior CABG. We aim to determine whether MDCT can be used reliably 
to predict graft patency in patients who have undergone coronary artery bypass grafting. 
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1.6.4 Chapter 6 
The identification of high risk patients in a safe, non-invasive and timely manner is 
essential for appropriate and efficient treatment. Understanding the mechanisms of 
plaque remodelling also has the potential to develop novel therapeutic strategies to aid in 
treatment and primary prevention of cardiovascular diseases. We will investigate the role 
of magnetic resonance imaging techniques to assess plaque volume and detect the 
characteristics associated with active inflammation following acute carotid plaque 
rupture. 
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1. 7 HYPOTHESES 
Non-invasive cardiac imaging modalities wi ll be employed to test the following 
hypotheses: 
• Computed tomography CAC scoring is reproducible. 
• Statin therapy reduces the progression of CAC. 
• Computed tomography angiography can be used reliably to determine coronary 
artery bypass graft patency. 
• MRI can be employed in a timely and reproducible manner to assess plaque 
volume and detect characteristics associated with active inflammation following 
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The long term consequences of vascular disease require the provision of substantial 
health care resources. With recent advances in computer assisted imaging technology, it 
has become possible to perform a wide range of medical imagi ng non-invasively. This 
has the potential both in terms of screening for the presence of vascular disease, and in 
terms of diagnosis of establi shed disease in order to target treatment and secondary 
prevention. In this thesis, two principle imaging modalities have been employed: 
computed tomography and magnetic resonance imaging. 
2.2 ETHICAL CONSIDERATIONS 
All studies were undertaken in accordance with the Declaration of Helsinki of the World 
Medical Association and with the approval of the local Research Ethics Committee. The 
written informed consent of each subject or patient was obtained before entry into the 
study. 
Ethical approval had been applied for and granted prior to my involvement in the 
SALTIRE study (Chapters 3 and 4)). For the work undertaken in Chapters 5 and 6, I 
submitted applications to the Local Research and Ethics Committee (LREC) which 
included drafting of patient and medical practitioners information summary, invitation 
leaflets , protocol summaries and consent forms as we11 as attendance at the commi ttee 
meeting. Applications were also submitted to the hospital Reasearch and Development 




2.3.1 Effect Of Statin Therapy On Coronary Artery Calcium Score 
The study population uses a sub-group of the Scottish Aortic stenosis Lipid-lowering 
Therapy, Impact on REgression (SALTIRE) trial which assessed the effect of aggressive 
lipid-lowering therapy in patients with calcific aortic stenosis (Cowell, Newby et al. 
2005). Patients aged > 18 years, with calcific aortic stenosis (grade 1-3 calcification on 
echocardiography) and a peak post-valve velocity of ~2.5 m/s were recruited from eight 
hospital centres across the South East of Scotland. Exclusion criteria were women of 
child-bearing potential without contraception, active or chronic liver disease, hi story of 
alcohol or drug misuse, severe mitral stenosis (valve area< L em\ severe mitral or aortic 
regurgitation, marked left ventricular dysfunction (ejection fraction <35%), planned 
aortic valve replacement, intolerance to statins, patients who were taking or would in the 
opinion of the treating physician benefit from statin therapy, baseline serum total 
cholesterol of <4.0 mmoi/L, and permanent pacemaker or cardiodefibrillator. For the 
purposes of the substudy, we also excluded patients who had no coronary artery 
calcification on computed tomography. 
Between March 2001 and April 2002, the blinded study co-ordinator randomised eligible 
patients by the minimisation technique using a dedicated locked computer program 
(Edinburgh University) which incorporated eight baseline variables: age, sex, smoking 
habit, hypertension, diabetes mellitus, serum cholesterol concentration, peak aortic jet 
velocity and aortic calcium score. Patients were assigned either to atorvastatin 80 mg 
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daily or matched placebo (Pfizer Ltd., Tadworth , UK) as a single daily dose using 
numbered containers. 
Patients were assessed at baseline, 2 months, 6 months and every 6 months thereafter for 
a minimum of 2 years. Clinical evaluation included assessment of functional status, 
adverse events and biochemical blood analysis. Serum hsCRP concentrations were 
determined using a highly sensitive immunonepbelometric method (Dade Behring Ltd, 
Milton Keynes, UK) as previously described. All patients underwent computed 
tomography within the month before randomisation to study therapy and at each annual 
visit. Randomised patients who were subsequently commenced on open label statin 
therapy by their attending physician were immediately scanned and withdrawn from 
further observation. 
2.3.2 CT Coronary Angiography In Detection Of Coronary Artery Bypass Graft 
Patency 
Patients who were scheduled for routine coronary angioplasty in the Department of 
Cardiology, Royal Infirmary of Edinburgh, were approached prior to their procedure and 
offered an information leaflet along with an informal discussion regarding the rationale 
behind the study, and what their invo lvement would entail. Patients were invited to join 
the study and followed up by letter and te lephone call fo llowing their procedure. If they 
agreed to participate in the study, a date for CTA was agreed. Three dedicated CT 
appointments were reserved for study participants in the Department of Radiology, Royal 
Infirmary of Edinburgh, each week. 
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Fifty consecutive patients who had undergone previous coronary artery bypass graft 
surgery and were listed for diagnostic coronary angiography between June 2004 and June 
2005 were recruited into the study. Exclusion criteria were the presence of implanted 
metallic cardiac devices which may interfere with image quality (prosthetic heart valves, 
implantable pacemaker or cardiodefibri llator), renal impairment, atrial fibrillation or 
those patients unable to tolerate the supine position. The study was conducted with the 
approval of the local research ethics committee, in accordance with the Declaration of 
Helsinki and the written informed consent of each subject. 
Coronary artery bypass graft patency was documented at the time of coronary 
angiography. Computed tomography was performed, where possible, within one month 
of coronary angiography. 
2.3.3 Novel Magnetic Resonance Imaging Techniques And Remodelling Of 
Complex Carotid Atherosclerosis 
Acute Neurovascular clinics take place twice weekly in the Western General Hospital, 
Edinburgh. I, assisted by my colleague Miss A Burdess, attended these clinics each week 
and sat in on the consultation with the Consultant Stroke Physician. Following patient 
consultation, information leaflet was provided and, if the patient was interested in 
participating in the study, they were accompanied to their Duplex ultrasound appointment 
in order to ascertain if they met the criteria outlined below. Following this, I scheduled 
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an appointment for the patient to attend for MRI scan, ideally within one week, by liasing 
with the research dedicated MRI scanning staff at the Western General Hospital. 
Twelve consecutive patients attending the acute neurovascular cl in ics at the Western 
General Hospital in Edinburgh were recruited in to the study. Inclusion criteria were 
symptoms and signs of an acute transient ischaemic attack, amaurosis fugax or stroke 
within 7-14 days of symptom onset and Doppler ultrasound documentation of ipsi lateral 
complex carotid plaque of >40% luminal stenosis to account for their clinical symptoms 
and presentation. Exclusion criteria were women of child bearing potential, renal or 
hepatic failure, severe or significant co-morbidity or being unable to tolerate the supine 
position. 
Magnetic resonance imaging was performed within four weeks of symptom onset. In 
order to assess reproducibility, the scan was repeated within one week. 
2.4 MDCT CORONARY ARTERY CALCIUM SCORING 
2.4.1 Computed Tomography 
Computed tomography was performed by a single blinded operator using a double-helix 
scanner (Twin n Flash; Philips Medical Systems (UK) Limited, Stevenage, UK) and 
calibrated against a standard phantom. Images were acquired in 2.7-mm slices (with a 
0.75 s fu ll 360° scan mode) through the region of the coronary arteries with a pitch of 0.7 
and an increment of 1.3 mm during held inspiration. Exposure factors were 120 kV at 
270 mAs and the scan angle was 360°. 
38 
Off-line analyses were conducted using an automated, computerised software program 
(Picker Cardiac Scoring). This employs a Agatston scoring method, producing sensitivity 
and specificity comparable to electron beam computed tomography. Each image was 
evaluated consecuti vely, with the threshold for the presence of calcium set at 130 
Hounsfield units (HU) with an area of greater than or equal to 1 mm2. For each grouping 
of pixels with an area greater than 1 rom and a peak intensity greater than 130 HU, the 
maximum attenuation was recorded. The Agatston score of each lesion was then 
calculated as the product of its area and a weighting factor based on its maximum 
attenuation (Table 2. L). A total coronary calcium score was determined by summing 
individual lesion scores for each of three anatomic sites (left anterior descending, 
circumflex and right coronary arteries) for each slice. The coronary artery calcium score 
has subsequently been divided into five categories for stratification of risk for a 
subsequent cardiac event (Table 2.2) (Rumberger, Brundage et al. 1999). 
I performed the CAC scoring for aJl patients on the PhHips workstation in the Borders 
General Hospital outside of normal working hours, when the scanner was not in routine 
clinical use. I was trained in the technique by Dr John Reid, Consultant Radiologist. The 
technique involves drawing an individual region of interest around the calcified areas 
(> 130HU) for each of the three vessels, on each CT image, thereby acquiring an 
individual vessel score and a total calcium score for each patient on each vi sit. 
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Table 2.1 CT attenuation weighting factors 
Weighting factor Hounsfield Unit range 




Table 2.2 CAC score- risk stratification 
CAC score Risk for a subsequent cardiac event 
0 nil 
1 - 10 Minimal 
11- 100 Mild 
lOl-400 Moderate 
>400 Severe 
Scans were scored using both the Agatston (130 HU threshold) and the modified 
Agatston (90 HU threshold) methods. The former has been shown to reduce 
interobserver and interscan variation compared to the threshold of 90 HU. To assess the 
reproducibility of the method, repeated baseline computed tomography scans were 
performed within 4 weeks of each other in an unselected random sample of 16 patients. 
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2.4.2 Reproducibility of MDCT Calcium Scoring 
To assess the reproducibility of the method, repeated baseline computed tomography 
scans were performed within 4 weeks of each other in a random sample of 16 patients. 
2.5 COMPUTED TOMOGRAPHY ANGIOGRAPHY 
2.5.1 Coronary Angiogram 
Coronary angiography was performed by an experienced cardiologist via standard 
percutaneous approach, using 6 French Judkins catheters. Images were obtained on a 
Innova digital flat plate system (Advantx, GE Medical Systems) following i.v. bolus 
injection of Niopam contrast agent (Bracco, Bucks, UK). Selective catheterisation of 
grafts or graft stumps was performed. 
2.5.2 MDCT Angiogram 
I supervised all patient studies, which involved meeting the patients in the Radiology 
Departmens prior to the study in order to ensure they understood the procedure and to 
obtain consent. I supervised the scans themselves, including gaining intravenous access 
and monitoring the patients fo llowing the scan to ensure that there was no sign of contrast 
reaction. 
MDCT angiography was performed using a 16-slice CT scanner (Aquilon; Toshiba, 
Tustin, CA). Prior to scanning, a 20- or 18- guage iv cannula was sited in the right arm. 
The patient was placed in a supine position in the gantry and the arms placed above the 
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patient's head with the ECG leads out of the scan range. The scan volume was defined 
based on expected location of the coronary arteries and grafts, following a scout view. In 
patients with known internal mammary artery grafts, this area was extended to the origin 
of the IMA at the proximal subclavian arteries. Fixed scanning variables included a 
gantry rotation time of 0.5 seconds, 16 x l mm detector collimation, 0.35 to 0.5 x 0.35 to 
0.5 mm pixel size, 135kV, 250 to 300 mA, 0.25 pitch, and inspiratory breath hold time 
20-30 seconds. lomeprol, 100 mL (400-strength, Bracco, Bucks, UK) contrast agent was 
administered intravenously. The suRECardio acquisition feature was utilised, which 
monitors the patient's heart rate for five consecutive beats, calculates an average and 
automatically selects optimal scan parameters. The contrast bolus was monitored using 
the SUREStart feature to initiate imaging when contrast density in the ascending aorta is 
160-180 HU. The images were obtained during inspiratory breath hold and 
retrospectively cardiac gated. The reconstruction set was limited to one phase at 75% of 
the R-R interval. From these images, one slice was selected to demonstrate best the three 
main coronary arteries at the mid-heart level. The selected slice was then reconstructed 
for the entire cardiac cycle at 20 ms intervals. From these images, the phase which best 
demonstrated the coronary arteries at this slice position were selected and the entire 
volume reconstructed at the selected phase (Figure I). The images were transferred to a 
dedicated workstation (Vitrea v3.5; Vital Images, Plymouth, MN). 
2.5.3 Data Analysis 
Two-dimensional axial, multi.planar reconstruction and three-dimensional reconstructions 
with volume rendering techniques were analysed by a radiologist who was familiar with 
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the cardiac anatomy but blinded to the result of the coronary angiogram. Image quality 
was graded in terms of eligible or insufficient (motion artefact, artefact caused by 
surgical clip) and eligible grafts were assessed in terms of patency and the presence and 
location of significant stenoses (stenosis >50% luminal diameter) were noted. The results 
ofMDCT were compared with coronary angiography, the gold standard reference. 
Radiation dose for invasive coronary angiography and MDCT angiography was 
calculated from the documented dose area product (cGycm2) and dose length product 
(mGycm) respectively. 
2.6 MAGNETIC RESONANCE ANGIOGRAPHY 
2.6.1 Imaging protocol 
Immediately prior to the first scan appointment, I met with all patients to go over the 
study and answer any questions as well as to obtain consent. I also filled in a checklist 
for each patient to ensure they had no metallic devices or contraindications to MR 
scanning. I supervised all scans including obtaining intravenous access, administering 
the contrast ageny and monitoring patients afterwards for any signs of contrast reaction. 
In order to assess feasibi lity, each subject underwent the following magnetic resonance 
imaging protocol. Subjects were placed in a head collar to reduce movement artefact. 
Carotid surface coils (bilateral four channel phased array) were app lied to maximise 
resolution, and scanning was cardiac synchronised to minimise pulsation artefacts. A 
research dedicated magnetic resonance imaging scanner (1.5T GE Echospeed) performed 
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a two dimensional time of flight (20 TOF) localiser view with a field of view FOV of 22 
em. The carotid bifurcation was identified from the Jocaliser sequence with subsequent 
sequences, based around the carotid bifurcation, consisting of axial Tl DIR 'black blood' 
with a field of view (FOV) of 14 em; proton density and T2 fast spin echo (FSE) with 
FOV of 13 em; and 3D TOF with FOV of 13 em before and after enhancement with an 
intravenous bolus of 0.1 mmol/kg Dotarem® (Gadoterate meglumine, Guerbet S.A., 
Paris, France). For each sequence this resulted in 9 slices, each 2mm thick, centred upon 
the carotid bifurcation of interest, thus giving coverage of 1.8 em. In order to assess 
reproducibility, the imaging protocol was then repeated within 2 weeks of the first 
assessment. Measurements of plaque area and volume were then compared between the 
two sets of scans. 
In order to assess neovascularisation, four subjects underwent an initial DIR axial scan 
(II slices, 2mm thick), followed by a fast spoiled gradient recalled echo sequence 
(FSPGR), with T-1 weighted images of the diseased carotid artery at 9 locations, centred 
on the carotid bifurcation. Following the method of Kerwin et al, 2003, each acquisition 
was repeated LO times, with a repetition interval of 16 seconds. Coincident with the 
second image in the sequence, 0.1 mmollkg of Dotarem® was injected at a rate of 2mLs/s 
via a power injector. 
2.6.2 Quantification of Carotid MR images 
Through collaboration with the Image Analysis Core of the Wellcome Trust Clinical 
Research Facility, digital images were quantitatively assessed using the development of 
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existing software. Using this software, the cross-sectional lumen and outer vessel wall 
boundaries were manually traced and cross-sectional areas calculated. Plaque area was 
defined as the vessel area minus the lumen area. Overall plaque area and volume were 
measured with reference to the carotid bifurcation to ensure consistency and 
comparability of study segments. Variation in pixel intensities within the plaque was also 
assessed. All scans, prior to measurements, were set at the same intensity level (Level 
1111, Width 222). The software package was then used to calculate the occurrences of 
different intensity levels within the plaque. Histograms of occurrences against intensity 
were then generated, with the hypothesis that heterogeneous plaques would yield 
differing histograms to homogeneous plaques. 
Data for each patient was assessed by an independent experienced neuroradiologist with 
respect to regional plaque densities using ex_isting criteria for lipid and fibrous plaques 
(Table 2.3). An overall Modified AHA Classification for MRI was allocated to each 
subject. This was then compared with the overall conventional histological AHA 
classification for Lhose subjects who had undergone endarterctomy. 
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Table 2.3 Conventional and Modified AHA Classification of Atherosclerotic Plaque 
Conventional AHA Classification r odified AHA Classification for MRI 
I 
ype 1: initiaJ lesion with foam cells Type I- ll: near-normal wall thickness, no 
~ype II: fatty streak with multip le ('alcifi cation 
foam cell layers 
~ype III: preatheroma with rrype III: di ffuse intimal thickening or small 
~xtracellu lar lipid pools jeccentric plaque with no calcification 
~ype IV: atheroma with a confluen rrype IV-V: plaque with a lipid or necrotic 
~xtracellular lipid core jcore surrounded by fi brous tissue with 
fype V: fibroatheroma I !Possible calcification 
~ype VI: complex plaque with rrype VI: complex plaque with possib l ~ 
!Possible surface defect, hemorrhage, jsurface defect, hemorrhage, or thrombus 
lor thrombus 
t ype VII: calctfied plaque I t ype VII: calcified plaque 
~ype VIII: fi brotic plaque without ifype Vill: fibrotic plaque without lipid core 
lipid core and with possib le small calci fications 
Finally, neovascularisation was determined by the degree of gadolinium enhancement of 
the plaque. After the acquisiti on of the nine locations around the carotid bifurcation, the 
area of the plaque on each location was manually traced as descr ibed above. These 
regions of interest (p laque areas) were then aligned for each o f the II time points and 
analysed fo r changes in signal intens ity over time. 
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2.7 STATISTICS 
2.7.1 Reproducibility of MDCT Coronary Calcium Scoring 
To assess the reproducibility of the method, repeated baseline CT scans were performed 
within four weeks of each other in a random sample of 16 patients. 
To determine the interscan correlation between calcium scores, the data were log 
transformed to reduce skew, and assessed using the method of Bland and Altman (Bland 
and Altman 1986). Bland Altman plots of the difference between the log total calcium 
score for each scan against the average between the two measurements were used to show 
the relationship between variabi lity and calcium distribution. Coefficient of variation for 
coronary artery caJcium score as measured by MDCT was calculated as the standard 
deviation divided by the mean. This is expressed as a percentage and allows comparison 
with reproducibility data in published literature. 
Analysis of Lhe effect of atorvastatin on the coronary calcium score was performed in 
collaboration with the Medical Statistics Department of the University of Edinburgh. 
Random coefficients models were used as the data had a hierarchical (or multilevel) 
structure. In the simplest regression problem, one static observation per covariate is 
collected, or multiple observations for just one subject. However, in hierarchical models 
such as we have, data are structured across multiple levels, i.e. multiple observations for 
multiple subjects so there will be some variability within each subject (within-subject 
varia nce) and some variability between subjects (between-subject variance). In these 
models, the variability at each level is distinct and needs to be accounted for separately at 
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each level in whatever analysis is undertaken. The random coefficients model is 
designed for doing just this whilst accounting for these multiple sources of variation and 
prevents a falsely statistically significant difference from being obtained. 
CAC scores are expressed in arbitrary units (AU) using the 130HU threshold. The 
calcium scores and hsCRP concentrations were not normally distributed and the data are 
presented as median with interquarti le ranges or mean and standard deviation following 
logarithmic transformation (log AU). The primary end-point, the rate of change of 
coronary calcium scores, was analysed using random coefficients models, for the reasons 
above, after logarithmic transformation of the scores. ln summarising the data, the 
change in coronary artery calcium scores was calculated by dividing the change between 
the baseline and final scores by the duration of follow-up. Rate of change in coronary 
calcium score is expressed as percentage change per year or as absolute change in the 
logarithm of the coronary artery calcium score. 
2.6.2 CT Coronary Angiography in Detection of Coronary Artery Bypass Graft 
Patency 
The results of MDCT were compared with coronary angiography, the gold standard 
reference. Sensitivity, specificity, positive and negative predictive value (PPV and NPV 
respectively) was calculated for the detection of graft patency by MDCT. Sensitivity was 
calculated as true patent/(true patent+ fa lse occluded) grafts. Specificity was calculated 
as the number of true occluded/(true occluded + false patent) grafts. The positive 
predictive value was a result of true patent/(true patent + false patent), and the negative 
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predictive value as true occluded/(true occluded + false occluded). The accuracy was 
determined by (true patent + true occluded)/total number of grafts. 95% confidence 
intervals were calculated by multiplying the standard error by 1.96. 
2.6.3 Novel Magnetic Resonance Imaging Techniques and Remodelling of 
Complex Carotid Atherosclerosis 
This was a preliminary study which aimed to establish the feasibility and reproducibility 
of novel magnetic resonance based techniques. An accurate estimate of statistical power 
was not possible. As a pilot study the data generated will permit a formal power 
calculation to be made for potential future clinical trials. For the parametric and 
volumetric variables described above, reproducibility was assessed by the method of 
Bland and Altman (Bland and Altman 1986), whereby plots of the difference between 
measurements against the average measurements were performed. The method of 
measurement was judged as being repeatable if 95% of the differences were of less than 
two standard deviations. 
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CHAPTER3 
REPRODUCffiiLITY OF THE CT CORONARY CALCIUM SCORE 
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3.1 ABSTRACT 
Introduction Coronary artery calcificat ion is virtually pathognomonic of 
atherosclerosis, and can be quantified in a non-invasive fashion using computed 
tomography. In order to be used reliably, measurements obtained should be reproducible 
and the interscan variability low. 
Methods In order to assess the reproducibility of the method, repeated baseline 
computed tomography scans were performed within 4 weeks of each other in an 
unselected random sample of 16 patients who took part in the Scottish Aortic Stenosis 
Lipid lowering Therapy, Impact on Regression tri al. Coefficients of variation were 
calculated. 
Results Overall, the differences on the log scale correspond to a coefficient of variation 
of 28% for both variables, but when restricted to the ten pairs with a geometric mean 
score above 100, the coefficient of variation was 10% for both variables. 
Conclusion We have demonstrated good reproducibility of coronary artery calcification 
scores in patients with scores of greater than 100 AU. 
3.2 INTRODUCTION 
Pathological, angiographic and fluoroscopic studies have shown that coronary artery 
calcification is virtually pathognomjc of atherosc1erosis (Frink, Achor et al. I 970; Rifkin, 
Parisi et al. 1979). CT is a well validated means of calculating the coronary artery 
calcium score, with a bigh sensitivity and negative predictive value when compared to 
fluoroscopy (Agatston, Janowitz et al. 1990). Coronary artery calcium score 
measurements have been used to stratify individual cardiac risk, to determine the 
presence of coronary disease and to monitor disease progression and response to therapy 
(Detrano, Doherty et al. 2000; Moser, O'Keefe et al. 2003; Pletcher, Tice et al. 2004). In 
order to monitor the progression of disease in a reliable fashion, the measurements 
obtained should be reproducible and the interscan variability low. Research, however, 
has cast doubts on the reliability of MDCT (Van Hoe, De Meerleer et al. 2003). Studies 
have highlighted the importance of the choice of timing during the cardiac cycle on the 
reconstruction window. One such study found that spiral CT enables reproducible 
quantification of coronary artery calcium in retrospectively ECG-gated images 
(Ohnesorge, Flohr et al. 2002), findings which have since been corroborated in other 
studies (Kopp, Ohnesorge et al. 2002). 
The Scottish Aortic Stenosis Lipid lowering Therapy, Impact on REgression (SALTIRE) 
trial was a prospective double blind randomised controlled study of intensive lipid 
lowering therapy in patients with calcific aortic stenosis (Cowell , Newby et al. 2005). As 
part of this trial, aortic valve and coronary artery calcium scores are measured using 
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helical computed tomography. The aim of this substudy was to assess reproducibility of 
the coronary artery calcium score. 
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3.3 METHODS 
The patient population and study protocol was as for Chapter 4, Progressive coronary 
calcification despite intensive lipid-lowering therapy: a randomised controlled trial. In 
order to assess the reproducibHity of the method, repeated baseline computed tomography 
scans were performed within 4 weeks of each other in a random sample of 16 patients. 
To determine the interscan correlation between calcium scores, the data were log 
transformed to reduce skew, and assessed using the method of Bland and Altman (Bland 
and Altman 1986). Bland Altman plots of the difference between the log total calcium 
score for each scan against the average between the two measurements were used to show 
the relationship between variability and calcium distribution. Coefficient of variation for 
coronary artery calcium score as measured by MDCT was calculated as the standard 
deviation divided by the mean, expressed as percentage. 
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3.4 RESULTS 
The reproducibility of the LAD coronary score and of the total coronary score was 
examined using the approach of Bland and Altman (Bland and Altman 1986). Without 
transformation, the difference between replicate observations tended to increase with the 
magnitude of the measurement. After logarithmic transformation, higher values showed 
stable differences, but differences were higher at the lowest scores (Figs. 3.1 and 3.2). 
Overall, the differences on the log scale correspond to a coefficient of variation of 28% 
for both variables, but when restricted to the ten pairs with a geometric mean score above 
I 00, the coefficient of variation was I 0% for both variables. 
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Figs 3.1 and 3.2. 
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Fig. 3.1 Bland Altman plot showing all reproducibi lity datasets. 
Fig. 3.2 Bland Altman plot showing reproducibility data for patients with a total CAC 
score of> I 00 AU. 
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3.5 DISCUSSION 
Histopathologic studies have demonstrated the correlation of coronary artery calcification 
with the presence of atherosclerosis (Rumberger, Simons et al. 1995). There appears to 
be a relationship between the extent of coronary calcification and the severity of luminal 
stenosis, as measured by invasive coronary angiography (Rumberger, Sheedy et al. 
1997). However, angiographic severity of luminal stenosis does not predict risk of future 
cardiac events, and is therefore of less use as a screening tool (Ambrose, Tannenbaum et 
al. 1988). On the other hand, a high coronary artery calcium score has been shown to be 
an independent predictor of coronary heart disease events (Wayhs, Zelinger et al. 2002; 
Pletcher, Tice et al. 2004) and indeed progression of coronary artery calcification has 
been shown to be greater in patients with future myocardial infarction (Raggi, Cooi l et al. 
2003). 
Controversy continues to ex ist over the role of coronary artery calcium screening and, as 
yet, there are no clear guidelines regarding specific indications. Its use has been 
suggested in screening of asymptomatic patients with other risk factors for cardiac 
disease (Moser, O'Keefe et al. 2003), in monitoring djsease progression (Shemesh, Apter 
et al. 2000; Budoff and Raggi 2001) and also in monitoring disease response to therapy 
(Callister, Raggi et al. 1998; Budoff, Lane et al. 2000; Budoff and Raggi 2001; 
Achenbach, Ropers et al. 2002). The final point, namely monitoring disease response to 
therapy, is the most controversial of all and, unti l recently, the only published data were 
retrospective or observational studies. Recently, however, definitive prospective 
randomised studies have proved that statio therapy has no effect on the progression of 
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coronary artery calcification, thereby removing the indication for serial scanning as a 
method of measuring di sease response to therapy (Arad, Spadaro et al. 2005; Raggi, 
Davidson et al. 2005). Nonetheless, whether the coronary artery calcium score is used as 
a one off screening modality for risk stratification, or as a way of monitoring disease 
progression, the importance of a reliable and reproducible method is paramount. 
Many different methods of calculating agreement have been described. Our results 
demonstrate that the range of arithmetic differences between the two repeated measures 
increased in proportion to the increase in the mean score. As described by Bland and 
Altman, logarithmic transformation of the scores results in a uniform distribution of 
differences over the range of the mean. The mean and standard deviation of differences 
can then be calculated and a meaningful comparison of differences evaluated across a 
range of coronary artery calcium scores. After logarithmic transformation, higher values 
showed stable differences. Overall, the differences on the log scale correspond to a 
coefficient of variation of 28% for both variables, but when restricted to the ten pairs with 
a geometric mean score above 100, the coefficient of variation was 10% for both 
variables. A threshold of> 100 has been shown to be highly sensitive for the prediction 
of future hard coronary events (Arad, Spadaro et al. 1996) therefore, importantly, we 
have demonstrated good reproducibility for scores which may be clinically significant. 
Similar results were achieved by Lu et al, who reported mean interscan variability of 
21.5% for the Agatston scoring method. They also found that variability decreased with 
increasing coronary calcium score (34.6% for a score of 11 -50 and 9.4% for a score of 
400 - 1000) (Lu, Budoff et al. 2002). Budoff et al report an even greater spread of 
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variability for different CAC scores, with variability of 61.3% for scores of 1-30, 
dropping to 8.2% for scores of >400 (Budoff, Kessler et al. 2008). Different methods of 
quantifying calcification exist, and it has been suggested that volumetric scores may be 
more reproducible than the Agatston scoring method. However, a study of 6814 patients 
found that calcium volume scores were only slightly more reproducible than the Agatston 
scoring method (mean relative difference 18.3 vs 20.1 for volumetric and Agatston score 
respectively) (Detrano, Anderson et al. 2005). 
Study Limitations 
Whilst we found our interscan variability to be similar to published data, we did not 
investigate other means of variability. Importantly, the scans were interpreted by a single 
operator which is not feasible in regular clinical practice. An obvious source of 
variability is interobserver variability which we did not assess. In addition, intra-observer 
variability must be considered. In order to assess the variability of a scoring method 
more accurately, it would be helpful to measure these additional parameters. 
3.6 CONCLUSION 
We have demonstrated good reproducibility of coronary artery calcification scores in 
patients with scores of greater than lOO AU. A threshold of >100 has been shown to be 
highly sensitive for the prediction of future hard coronary events (Arad, Spadaro et al. 
1996) therefore, importantly, we have demonstrated good reproducibility for scores 
which may be clinically significant. 
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CHAPTER4 
PROGRESSIVE CORONARY CALCIFICATION DESPITE 
INTENSIVE LIPID-LOWERING THERAPY: 
A RANDOM/SED CONTROLLED TRIAL 
Houslay ES, Cowell SJ, Prescott RJ, Reid J, Burton J, Northridge DB, Boon NA, 
Newby DE. 
Progressive coronary calcification despite intensive lipid-lowering treatment: a 





Objectives Observational studies have suggested that statio therapy may induce 
regression of coronary artery calcification. In a substudy of a trial recruiting patients with 
calcific aortic stenosis, we evaluated the effect of intensive lipid-lowering therapy on 
coronary artery calcification. 
Methods In a double blind randomised controlled trial, I 02 patients with calcific aortic 
stenosis and coronary artery calcification were randomised using the minimisation 
technique to atorvastatin 80 mg daily or matched placebo. Coronary artery calcification 
was assessed annually by helical computed tomography. 
Results Forty-eight patients were randomised to atorvastatin and 54 to placebo with a 
median follow-up of 24 months (interquartile range, 24-30). Baseline characteristics and 
coronary artery calcium scores were similar in both groups. Atorvastatin therapy reduced 
serum low-density lipoprotein cholesterol (-53%; P<O.OO I) and C-reactive protein ( -49%; 
P<O.OOl ) concentrations wbjJst there was no change with placebo ( -7% and + 17%; 
P>0.95 for both). The rate of change in coronary artery calcification was 26%/yr (0.234 
(SE 0.037) logAU/yr; n=39) in the atorvastatin group and 18%/yr (0.167 (SE 0.034) log 
AU/yr; n=49) in the placebo group: geometric mean difference of + 7%/yr (95% 
confidence intervals -3% to + 18%; P=0.18). There was no correlation between serum 
low-density lipoprotein concentrations and the rate of progression of coronary 
calcification (r=0.05, P=0.62). 
Conclusion In contrast to previous observational studies, this randomised controlled 
trial has shown that, despite reducing systemic inflammation and halving serum low-
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density lipoprotein cholesterol concentrations, statin therapy does not have a major effect 
on the rate of progression of coronary artery calcification. 
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4.2 INTRODUCTION 
Coronary artery calcification is an independent risk factor for coronary heart disease with 
even low coronary calcium scores doubling the risk of coronary events (Pletcher, Tice et 
at. 2004). The relative risk associated with coronary calcification greater than that 
associated with established factors such as smoking, hypertension and diabetes mellitus. 
Progression of coronary artery calcification is associated with a higher incidence of 
coronary events even in those people who are asymptomatic at the time of initial 
scanning (Raggi, Cooil et at. 2003). Thus, the presence of coronary artery calcification is 
not only indicative of atheromatous plaque disease, but its progression may correspond 
with cardiovascular event rates. 
Statin therapy has a proven role in the primary (Shepherd, Cobbe et al. 1995; Downs, 
Clearfield et at. 1998) and secondary prevention (1994; 1998; Lewis, Moye et at. 1998) 
of cardiovascular disease with incremental benefits seen with more intensive reductions 
in serum cholesterol concentrations (2002). Previous studies (Callister, Raggi et al. 1998; 
Achenbach, Ropers et al. 2002) have reported that statins can halt the progression and 
may even induce regression of coronary artery calcification. Indeed, the rate of 
progression of coronary artery calcification correlates with the average serum low-density 
lipoprotein (LDL) cholesterol concentration (Callister, Raggi et aJ. 1998). This has Jed to 
the use of computed tomography to monitor disease progression and response to 
treatment, particularly statin therapy. However, two recent trials have failed to 
demonstrate a benefit of statin therapy on the progression of coronary artery calcification 
in asymptomatic individuals (Arad, Spadaro et al. 2005; Raggi, Davidson et al. 2005). 
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The Scottish Aortic Stenosis Lipid lowering Therapy, Impact on REgression (SAL TIRE) 
trial was a prospective double blind randomised controlled study of intensive lipid 
lowering therapy in patients with calcific aortic stenosis (Cowell, Newby et al. 2005). As 
part of this trial, aortic valve and coronary artery calcium scores are measured using 
helical computed tomography. The aim of this substudy was to assess the effect of 
atorvastatin 80 mg daily on the rate of progression of coronary artery calcification in 
patients with calcific aortic stenosis. 
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4.3 METHODS 
4.3.1 Patient Population 
Patients aged > 18 years, with calcific aortic stenosis (grade l-3 caJcification on 
echocardiography (Rosenhek, Binder et al. 2000)) and a peak post-valve velocity of ~2.5 
m/s were recruited from eight hospital centres across the South East of Scotland. 
Exclusion criteria were women of child-bearing potential without contraception, active or 
chronic liver disease, history of aJcohol or drug misuse, severe mitral stenosis (valve area 
< 1 cm2), severe mitral or aortic regurgitation (Zoghbi, Enriquez-Sarano et al. 2003), 
marked left ventricular dysfunction (ejection fraction <35%), planned aortic valve 
replacement, intolerance to statins, patients who were taking or would in the opinion of 
the treating physician benefit from statin therapy, baseline serum total cholesterol of <4.0 
mmoi/L, and permanent pacemaker or cardiodefibrillator. For the purposes of the 
substudy, we also excluded patients who had no coronary artery calcification on 
computed tomography. The study was conducted with the approval of all the regional 
research ethics committee and in accordance with the Declaration of Helsinki. Written 
informed consent was obtained from each subject. 
4.3.2 Study Protocol 
Between March 2001 and Apri I 2002, the blinded study co-ordinator randornised e)jgible 
patients by the minimisation technique (Treasure and MacRae 1998) using a dedicated 
locked computer program (Edinburgh University) which incorporated eight baseline 
variables: age, sex, smoking habit, hypertension, diabetes mellitus, serum cholesterol 
concentration, peak aortic jet velocity and aortic calcium score. Patients were assigned 
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either to atorvastatin 80 mg daily or matched placebo (Pfizer Ltd., Tadworth, UK) as a 
single daily dose using numbered containers. 
Patients were assessed at baseline, 2 months, 6 months and every 6 months thereafter for 
a minimum of 2 years. C linical evaJuation included assessment of functional status, 
adverse events and biochemical blood anaJysis. Serum highly sensitive C-reactive 
protein (hsCRP) concentrations were determined using a highly sensitive 
immunonephelometric method (Dade Behring Ltd, Mi lton Keynes, UK). All patients 
underwent computed tomography with.in the month before randomisation to study 
therapy and at each annual visit. Randomised patients who were subsequently 
commenced on open label statin therapy by their attending physician were immediately 
scanned and withdrawn from further observation. 
4.3.3 Computed Tomography 
Computed tomography was performed by a single blinded operator using a double-helix 
scanner (Twin II Flash; Philips Medical Systems (UK) Limited, Stevenage, UK) and 
calibrated against a standard phantom. Images were acquired in 2.7-mm slices (with a 
0.75 s full 360° scan mode) through the region of the coronary arteries with a pitch of 0.7 
and an increment of 1.3 mm during held inspiration. Exposure factors were 120 kV at 
270 mAs and the scan angle was 360°. Off-line analyses were conducted using an 
automated, computerised software program (Picker Cardiac Scoring). This employs a 
Agatston scoring method (Agatston, Janowitz et al. 1990), producing sensitivity and 
specificity comparable to electron beam computed tomography (Carr, Crouse et al. 2000). 
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Scans were scored using both the Agatston (130 HU threshold) and the modified 
Agatston (90 HU threshold) methods (Shemesh, Apter et aJ. 1995). The former has been 
shown to reduce interobserver and interscan variation compared to the threshold of 90 
HU (Goldin, Yoon et al. 2001 ). 
4.3.4 Data Analysis and Statistics 
Coronary artery calcium scores are expressed in arbitrary units (AU) using the 130 HU 
threshold. The calcium scores and hsCRP concentrations were not normally distributed 
and data are presented as median with interquartile ranges or mean and standard 
deviation following logarithmic transformation (log AU). The primary end-point, the 
rate of change of coronary calcium scores, was analysed using random coefficient models 
(Brown and Prescott 1999) after logarithmic transformation of the scores. In 
summarising the data, the change in coronary artery calcium scores was calculated by 
dividing the change between the baseline and final scores by the duration of follow-up. 
Rate of change in coronary calcium score is expressed as percentage change per year or 
as absolute change in the logarithm of the coronary artery calcium score. As well as 
tests of significance, 95% confidence intervals are reported as appropriate. Statistical 
significance was taken as a two-sided P value <0.05. 
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4.4 RESULTS 
Of 155 patients recruited into the SALTIRE trial, 102 had coronary calcification at 
baseline (Figure 4.1 ; CONSORT flow diagram of patients recruited into the trial and 
substudy) of whom 88 had at least two scans. Coronary calcification predominated in the 
left anterior descending artery (100% of patients) although it was also present in the 
circumflex (33%) and right (27%) coronary arteries. Baseline characteristics and 
coronary artery calcium scores were well matched in both treatment groups (Table 4.1) in 
the 88 evaluable subjects. 
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Table 4.1 Baseline subject characteristics 
Age (years) 
Sex(% male) 
Body mass index 






Coronary heart disease 
Cerebrovascular disease 






Blood Pressure (mmHg) 
Systolic blood pressure 



















82 (1 1) 
Total cholesterol (mmoi/L) 5.7 (0.9) 
LDL cholesterol (mmoi/L) 3.6 (0.8) 
HDL cholesterol (mmoi/L) 1.5 (0.4) 
Chol:HDL ratio 4.2 ( 1.2) 
Triglycerides (mmol/L) 1.5 (0.8) 






















4.0 (J .0) 
1.4 (0.7) 
Left anterior descending 11 2 (40- 285) 207 (76 - 461) 
Circumflex 0 (0- 9) 0 (0- 4) 
Right 0 (0-29) 0 (0- 0) 
Total coronary score 195 (57 - 448) 235 (83 - 526) 
Log total coronary score (log AU) 2.16 (0.68) 2.30 (0.65) 
Continuous variables stated as mean (SD) or median (interquartile range). 
Categorical variables stated as percent. 
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4.4.1 Effect of Atorvastatin Treatment 
Patients were followed up for a median of 24 months (interquartile range, 24 to 30). 
Atorvastatin 80 mg daily more than halved serum LDL cholesterol concentrations (53 
(SD 19) %; p<O.OOl), whiJst placebo had no effect (Figure 4.2). This reduction in serum 
LDL cholesterol concentrations was associated with a marked decrease in serum C-
reactive protein concentrations from 1.95 (interquartile range, 1.15 to 4.86) to 1.00 (0.49 
to 2.31) mg/L (Wilcoxon Signed Rank, P<O.OO I; Figure 2). Atorvastatin was well 
tolerated with discontinuation of study medication in two patients on placebo and five 
patients on atorvastatin, predominantly as a result of gastrointestinal upset. One patient 
on atorvastatin had an increase in creatine kinase of >5-times the upper limit of normal 
' 
without symptoms of myositis, and was withdrawn at the request of the Data Monitoring 
Committee. There were no cases of rhabdomyolysis. 
'- 4.4.2 Coronary Artery Calcium Score 
Atorvastatin did not affect the rate of progression of CAC score (Figure 4.2). Similar 
results were obtained when employing the 90 HU threshold (42 (SD 73) %/yr in the 
atorvastatin group and 29 (SD 37) %/yr in the placebo group; P=0.24). Serum LDL 
cholesterol concentrations did not correlate with the rate of progression of coronary artery 
calcification (r=0.05, P=0.62). 
The primary analysis of the rates of change of coronary artery calcium scores was 
conducted on the logarithms of the scores using random coefficients models (Brown and 
Prescott 1999). This showed no difference between the average rates of change in the 
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two treatment arms (P=O.l8). The mean coronary calcium score increased by 0.234 (SE 
0.037) log AU/yr in the atorvastatin group and 0.167 (SE 0.034) log AU/yr in the placebo 
group. These figures correspond to a 26 %/yr increase in the atorvastatin group and 18 
%/yr in the placebo group. The geometric mean (adjusted for baseline) is 7% higher at 
one year on atorvastatin compared to placebo, with 95% confidence Umits ranging from 
3% lower to 18% higher. The observed annual changes in CAC scores, calculated from 
the first to the last visit, are summarised in Figure 4.3. 
As anticipated in such a modest clinical trial, there were no significant differences in all-








Logarithm or Coronary 
Artery Calcium Score 
(Log AU) 2 
0 
1.2 
Logarithm ofSenun 0.8 
































Progression of (A) coronary artery calcification, (B) serum C-reactive protein concentrations 
(P<O.OOl, atorvastatin versus placebo), and (C) serum low-density lipoprotein (LDL) cholesterol 
concentrations (P<O.OOl, atorvastatin versus placebo) in patients treated with atorvastatin 80 mg 
daily (solid circles) or matched placebo (open squares). 
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Figure 4.3 
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Absolute rate of change in CAC score (AU per year for patients treated with atorvastatin 80 mg (solid circles) or matched placebo (open squares)). 
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4.5 DISCUSSION 
We have confirmed that, despite marked reductions in serum LDL cholesterol and C-
reactive protein concentrations, atorvastatin 80 mg daily did not halt the progression, or 
induce regression, of coronary artery calcification in patients with calcific aortic stenosis. 
Consistent with recent trials of asymptomatic individuals (Arad, Spadaro et al. 2005; 
Raggi, Davidson et al. 2005), our findings are in marked contrast to previous 
observational studies and suggest that the potential beneficial effects on coronary artery 
calcification have been over estimated. 
Previous observational and non-randomised prospective studies (Callister, Raggi et al. 
1998; Achenbach, Ropers et aJ. 2002) have suggested that reductions in serum LDL 
cholesterol concentrations decrease the progression of coronary calcification. However, 
not all observational studies have demonstrated consistent findings. In the largest 
observational study of 182 patients, Hecht and colleagues recently found no difference in 
the progression of coronary calcium scores in patients who were maintained on lipid 
lowering therapy and achieved significant reductions in serum LDL cholesterol 
concentrations (Hecht and Harman 2003). Observational data may be misleading and 
prospective randomised controlled trials are necessary to confirm or to refute these 
interesting preliminary observations. The recent BELLES trial (Raggi, Davidson et al. 
2005) found no differential effect of pravastatin (40 mg daily) and atorvstatin (80 mg 
daily) on the progression of coronary artery calcification in 615 hyperlipidaemic post-
menopausal women. However, study fo llow-up was brief (1 year) and there was no 
p lacebo control group. The St Francis Heart Study (Arad, Spadaro et al. 2005) 
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randomised 1,005 asymptomatic middle-aged men and women with high coronary artery 
calcium scores to combination atorvastatin 20 mg, vitamin C I g and vitamin E (alpha 
tocopherol) l 000 U daily or matching placebos. After 4.3 years of fo llow-up, there were 
no differences in the rate of progression of coronary artery calcification. 
We have conducted a double bHnd randomised controlled trial using helical computed 
tomography in patients with aortic stenosis. Minimisation technique ensured good 
matching of the baseline characteristics of the patient population and reproducibility 
studies confirmed the validity of our repeated assessments. Although documenting very 
similar rates of progression of coronary calcification to previous studies (Calli ster, Raggi 
et al. 1998; Achenbach, Ropers et al. 2002; Hecht and Harman 2003), we have not 
observed a reduction in coronary calcification with intensive lipid lowering therapy 
despite more than halving serum LDL cholesterol concentrations. 
Statio therapy has been extremely successful in the primary and secondary prevention of 
cardiovascular disease. Why then have we and others not observed a beneficial effect of 
statin therapy on coronary artery calcification? Unstable atherosclerotic plaques have a 
large lipid rich core, a preponderance of macrophages and foam cells, and a thin fibrous 
cap containing few smooth muscle cells (Davies 1997). It has been suggested that 
calcified lesions may be relatively more stable (Mintz, Popma et aJ. 1995), indicating a 
possible protective role of calcification in coronary plaques. Statio therapy produces 
many of its beneficial effects through plaque stabi lisation. In both primate (Stary 2001) 
and swine (Daoud, Jarmolych et al. L 98 1) models, anti-atherosclerotic interventions are 
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associated with an increase in vascular fibrous tissue and calcification. This calcium 
deposition continues during the initial phase of plaque regression due to the death of 
foam cells and an increase in necrotic tissue. Thus vascular calcification may play a role 
in the initial stabilisation of atherosclerotic plaques. This is consistent with our findings 
and would account for the lack of effect on the progression of coronary artery 
calcification despite a reduction in seiUm C-reactive protein concentrations. 
After the initial stabilisation of the atherosclerotic plaque, it would be anticipated that 
subsequent progression of coronary calcification would be inhibited. The present study 
was brief, and fo llow up was only continued for a median of 2 years. It would be 
important to extend our observations to 5 or more years to assess properly the impact of 
statin therapy on the long-term progression of coronary artery calcification. However, it 
should be acknowledged that the clinical benefits of statin therapy are apparent within the 
first few years ( 1998; Lewis, Moye et al. 1998; 2002), and in some cases the first few 
months (Schwartz, Oliver et al. 1998), of therapy. Moreover, the St Francis Heart Study 
demonstrated no beneficial effects despite 4.3 years of follow-up (Arad, Spadaro et al. 
2005). 
On the basis of previous non-randomised studies (Achenbach, Ropers et al. 2002), the 
practice of performing serial CT scans to monitor disease progression and the response to 
treatment has become widespread, especially in the North America. Our data, and that of 
the St Francis Heart Study (Arad, Spadaro et al. 2005) and the BELLES study (Raggi, 
Davidson et al. 2005), indicate that repeated scanning to assess response to statin therapy 
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is not justified. Indeed, the radiation dose incurred for such serial scans poses potential 
health risks, particularly when employing multidetector computed tomography scanners. 
4.5.1 Study Limitations 
There are several factors that should be taken into account when considering the results 
of our study. This was a substudy of the SAL TIRE trial (Cowell, Newby et al. 2005) that 
recruited only patients with calcific aortic stenosis. However, our findings are consistent 
with two recent randomised controlled trials in asymptomatic younger individuals 
without valvular heart di sease (Arad, Spadaro et al. 2005; Raggi, Davidson et al. 2005). 
Our study therefore suggests that failure of statins to restrict the progression of coronary 
artery calcification can be extended to include patients with valvular heart disease as well 
as more elderly populations. Moreover, our findings suggest that lack of benefit seen in 
the St Francis Heart Study is not attributable to the modifying effects of antioxidant 
vitamins. 
When compared with electron beam computed tomography, the accuracy of helical 
computed tomography in detecting coronary artery calcification has been questioned 
(Carr, Crouse et al. 2000) (Qanadli, Mesurolle et al. 2001). Technological advances 
have also meant that double-helical scanners have now been overtaken by 64 slice 
scanners. At trial inception, the double-helix scanner was "state-of-the-art" and it would 
have been inappropriate to replace the scanner during the conduct of the trial. Moreover, 
our approach has been previously validated and we have demonstrated good 
reproducibi lity of coronary artery calcification scores in patients with scores of greater 
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than 100 AU. We do not believe the absence of a major beneficial effect on coronary 
artery calcification is attributable to our methodology. We acknowledge the fact that our 
population size is modest; however, tbe 95% con~fidence intervals are able to exclude a 
relative reduction in progression of coronary artery calcification of >3%/yr. We therefore 
suggest tbat if lipid-lowering therapy does reduce the progression of coronary artery 
calcification then the effect is rather small. 
Controversy exists over the method of quantification of coronary artery calcification. 
The Agatston method is traditionally employed but this may overestimate the coronary 
calcium score in newer generation scanners with reduced slice thickness due to partial 
voluming. More recent methods include the volume (Callister, Cooil et al. 1998) and the 
coronary calcium mass (Hong, Becker et al. 2002) scores, although neither are superior to 
the Agatston score in terms of reproducibility from consecutive scans in an individual 
patient (Rumberger and Kaufman 2003). 
4.5.2 Conclusion 
We conclude that intensive lipid lowering therapy does not halt the progression, or induce 
regression, of coronary artery calcification. Although coronary artery calcium scores 
correlate well with the presence of atherosclerosis and predict future coronary risk, our 
findings confirm that there is currently no role for monitoring progression of coronary 
artery calcification in order to assess the response to lipid lowering therapy. 
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CHAPTERS 
NON-INVASIVE ASSESSMENT OF CORONARY ARTERY BYPASS 
GRAFT PATENCY USING COMPUTED TOMOGRAPHY 
ANGIOGRAPHY 
Houslay ES, Lawton T, Sengupta A, Uren NG, McKillop G, Newby DE. 
Non-invasive assessment of coronary artery bypass graft patency using 16-slice 
computed tomography angiography. J Cardiothorac Surg. June 5;2(1):27. 
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5.1 ABSTRACT 
Background Invasive coronary angiography is tbe gold standard means of imagi ng 
bypass vessels and carries a small but potentially serious risk of local vascular 
complications, including myocardial infarction, stroke and death. 
Aim To evaluate computed tomography as a non-invasive means of assessing graft 
patency. 
Design Comparative observational study. 
Methods Fifty patients with previous coronary artery bypass surgery who were listed for 
diagnostic coronary angiography underwent contrast enhanced computed tomography 
angiography using a 16-slice multidetector computed tomography scanner. Images were 
retrospectively gated to the electrocardiogram and two dimensional axial, multiplanar and 
three dimensional reconstructions acquired. Sensitivity, specificity, positive and negative 
predictive value, accuracy and level of agreement for detection of graft patency by 
multidetector computed tomography. 
Results A total of 116 grafts were suitable for analysis. The specificity of CT for the 
detection of graft patency was 100%, with a sensitivity of 92.8%, positive predictive 
value 100%, negative predictive value 85.8% and an accuracy of 94.8%. The kappa 
value of agreement between the two means of measuring graft patency was 0.9. Mean 
radiation dose for coronary angiography was 9.0±7.2 mSv and for computed tomography 
was 18.5±4 mSv. Pooled analysis of eight studies, incorporating 932 grafts, confirmed a 
96% accuracy for the detection of graft patency by multidetector computed tomography. 
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Conclusions Computed tomography is an accurate, rapid and non-invasive method of 
assessing coronary artery bypass graft patency. However, this was achkved at the 
expense of an increase in radiation dose. 
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5.2 INTRODUCTION 
Coronary artery bypass grafting (CABG) was first performed in 1967 by Garrett et 
ai,(Garrett, Dennis et aJ. 1973) who successfully employed a saphenous vein graft (SVG) 
for the treatment of coronary artery disease. This procedure has now become a 
widespread treatment for intractable angina and, in high risk patients, improves 
survival.(Davis, Chaitman et al. 1995) However, the benefits of surgery may be lost with 
graft failure or occlusion. Vein graft patency has been found to be reduced to 81% at one 
year, 75% at 5 years and less than 50% at 15 years.(Fitzgibbon, Kafka et al. 1996) This 
has led to the increasing use of arterial conduits, such as left internal mammary grafts 
(LIMA), that are associated with improved long term (1 0-15 year) patency and 
survival. (Barner, Standeven et al. 1985; Cameron, Davis et al. 1996) 
Vein graft occlusion may occur early or late and is due to three distinct, well described 
disease processes. Acute graft fai lure and thrombosis may occur in the first 30 days 
postoperatively, and affects up to 12% of vein grafts.(Fitzgibbon, Kafka et al. 1996) 
Neointimal hyperplasia occurs between one month and a year, and is the result of 
accumulation of smooth muscle cells and extracellular matrix in the intimal compartment. 
While this rarely causes clinically significant stenosis,(Lie, Lawrie et al. 1977) it provides 
the foundation for the development of graft atheroma. Late graft failure results from an 
accelerated form of atherosclerosis caJled 'graft vasculopathy'. This process 
predominates beyond the first year after surgery and is present in 17% of grafts at 6 years 
and 46% of grafts at 11 years.(Bourassa, Fisher et al. 1985) 
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The gold standard method of assessing graft patency is coronary angiography. This 
invasive procedure carries the small risk (I 0 in 1000) of potentially serious local vascular 
complications, including myocardial infarction, stroke and death. Studies have shown 
that electi ve coronary angiography in clinically stable patients with saphenous vein grafts 
carries a 0.08% risk of myocardial i.nfarction, while 0.7% of subjects experienced 
clinically important complications. The risk of myocardial infarction increased to 1.3% 
for urgent studies.(Gobel, Stewart et al. 1998) The assessment of graft patency in a non-
invasive readily applicable manner would have major benefits for the management and 
treatment of patients with prior CABG. The large calibre and more static location of 
bypass grafts make them particularly su itable for investigation by potential non-invasive 
imaging modalities. Computed tomography angiography was first described as a means 
of determining bypass graft patency in 1980.(Brundage, Lipton et al. 1980; Guthaner, 
Brody et al. 1980) With advances in spiral and multidetector computed tomography 
(MDCT) technology, there has emerged a growing body of evidence to support the use of 
computed tomography for non-invasive bypass graft assessment.(Engelmann, von 
Smekal et al. 1997; Engelmann, Knez et al. 2000; Nieman, Oudkerk et al. 200 I; 
Burgstahler, Kuettner et al. 2003; Dewey, Lembcke et al. 2004; Marano, Storto et al. 
2004; Schlosser, Konorza et al. 2004; Willmann, Weishaupt et al. 2004; Song, Ito et al. 
2005) Using the reference gold-standard of invasive coronary angiography, we aimed to 
assess whether contrast enhanced MDCT can reliably predict graft patency in patients 
who have previously undergone CABG. 
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5.3 METHODS 
5.3.1 Patient population 
Fifty consecutive patients who had undergone previous coronary artery bypass graft 
surgery and were listed for diagnostic coronary angiography between June 2004 and June 
2005 were recruited into the study. Exclusion criteria were the presence of implanted 
metallic cardiac devices which may interfere with image quality (prosthetic heart valves, 
implantable pacemaker or cardiodefibrillator), renaJ impairment, atrial fibrillation or 
those patients unable to tolerate the supine position. The study was conducted with the 
approval of the local research ethics committee, in accordance with the Declaration of 
Helsinki and the written informed consent of each subject. 
5.3.2 Coronary Angiogram 
Coronary angiography was performed by an experienced cardiologist via standard 
percutaneous approach, using 6 French Judkins catheters. Images were obtained on a 
lnnova digital flat plate system (Advantx, GE Medical Systems) following i.v. bolus 
injection of Niopam contrast agent (Bracco, Bucks, UK). Selective catheterisation of 
grafts or graft stumps was performed. 
5.3.3 MDCT Angiogram 
MDCT angiography was performed using a L6-slice MDCT scanner (Aquilon; Toshiba, 
Tustin, CA). The scan volume was defined based on expected location of the coronary 
arteries and grafts, following a scout view. In patients with known internal mammary 
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artery grafts, this area was extended to the origin of the IMA at the proximal subclavian 
arteries. Fixed scanning variables included a gantry rotation time of 0.5 seconds, 16 x 1 
mm detector collimation, 0.35 to 0.5 x 0.35 to 0.5 mm pixel size, 135kV, 250 to 300 rnA, 
0.25 pitch, and inspiratory breath hold time 20-30 seconds. Jomeprol, 100 mL (400-
strength, Bracco, Bucks, UK) contrast agent was administered intravenously. The 
SURECardio acquisition feature was utilised, which monitors the patient's heart rate for 
five consecutive beats, calculates an average and automatically selects optimal scan 
parameters, in order to optimise intravenous contrast concentration at the time of image 
acquisition. The images were obtained during inspiratory breath hold and retrospectively 
cardiac gated. The reconstruction set was limited to one phase at 75% of the R-R 
interval. From these images, one slice was selected to demonstrate best the three main 
coronary arteries at the mid-heart level. The selected slice was then reconstructed for the 
entire cardiac cycle at 20 ms inte rvals. From these images, the phase which best 
demonstrated the coronary arteries at this slice position were selected and the entire 
volume reconstructed at the selected phase (Figure 5.1). The images were transferred to a 
dedicated workstation (Vitrea v3.5; Vital Images, Plymouth, MN). 
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Figure 5.1 Three dimensional reconstruction with volume rendering techniques 
demonstrating saphenous vein grafts (SVG) to the posterior descending branch of the 
right coronary artery (RCA) and obtuse marginal branch of the circumflex artery (OM) 
and left internal mammary graft (LIMA) to left anterior descending artery (LAD). 
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5.3.4 Data Analysis 
Two-dimensional axial, multiplanar reconstmction and three-dimensional reconstmctions 
with volume rendering techniques were analysed by a radiologist who was fam iliar with 
the cardiac anatomy but blinded to the result of the coronary angiogram. Image quality 
was graded in terms of e ligible or insufficient (motion artefact, artefact caused by 
surgical clip) and eligible grafts were assessed in terms of patency and the presence and 
location of significant stenoses (stenosis >50% lumjnal diameter) were noted. The results 
of MDCT were compared with coronary angiography, the gold standard reference. 
Sensitivity, specificity, positive and negative predictive value (PPY and NPV 
respectively) was caJculated for the detection of graft patency by MDCT. Radiation dose 
for invasive coronary angiography and MDCT angiography was caJculated from the 
documented dose area product (cGycm2) and dose length product (mGycm) respectively. 
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5.4 RESULTS 
Patients were predominantly male, with a mean graft age of 7±5 years (Table 5.1) and the 
majority (66%) were on beta-blockers. Mean heart rate was 67 beats per minute (range 
52-89). MDCT angiography was performed on all 50 patients a mean of 55 days 
following conventional angiography (range 40-74). Of these patients, two studies were 
not of sufficient diagnostic quality due to movement artefact and technical failure, 
thereby excluding 6 grafts from analysis. A further six grafts were non-diagnostic on 
MDCT angiography and a further one excluded due to stent insertion with subsequent in-
stent stenosis between recruitment to the study and time of MDCT. Of 129 grafts, a total 
of 116 were suitable for analysis. There were no complications as a result of the MDCT 
or invasive diagnostic angiography. 
MDCT correctly identified 77 of 83 patent grafts and 33 of 33 occluded grafts (Table 
5.2). The sensitivity for detection of graft patency was 92.8%, specificity 100%, positive 
predictive value 100%, negative predicti ve value 84.6% and accuracy 94.8%. The main 
discrepancies lie in the repotting of IMA grafts, where there were a significant proportion 
of false occlusions (Table 5.3). There was a very good strength of agreement between 
the two imaging modalities (Cohen's K=0.9). 
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Table 5.1 Baseline Subject Characteristics 
No. of patients so 
Sex(% male) 86 
Mean age (SD) 66 (9) years 
Heart Rate (Mean, Median, Range) 67' 68, 52-89 
No. of bypass grafts 116 
No. of IMA grafts 35 
• IMA~LAD 30 
• IMA ~ OM 2 
• IMA ~Diagonal 2 
• IMA ~ Circumflex I 
No. ofSVGs 77 
• sva~oM 26 
• sva~RcA 25 
• sva~LAD 13 
• SVG ~ Diagonal 7 
SVG ~posterior descending 
6 • 
Radial artery grafts 4 
• ---+OM 3 
• ---+ posterior descending 1 
Mean graft age (SD) 7 (5) years 
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Table 5.2 Graft characteristics 
Angiography MDCT 
patent occluded True False True False 
patent patent occluded occluded 
Overall 
n=116 83 33 77 0 33 6 
IMA 
n=35 30 5 25 0 5 5 
SVG 
n=77 52 25 51 0 25 1 
Other 
n=4 1 3 1 0 3 0 
Table 5.3 Diagnostic accuracy of MDCT for detection of graft patency 
Sensitivity % Specificity % PPV% NPV % Accuracy % 
(95% C./.) (95% C.J.) (95% C.J.) (95% C.J.) (95% C./.) 
Overall 92.8 100 100 84.6 94.8 
n=116 (84.9- 97.3) (91.3 -100) (96.2 -100) (69.5- 94.1) (89.1- 98.1) 
IMA 
grafts 82.8 100 100 50 85.3 
n=35 
SVG 
n=77 98.1 100 100 96.3 98.7 
Other 
n=4 100 100 100 100 100 
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5.4.1 Radiation exposure 
The mean radiation exposure for coronary angiography was 9.0±7.2 mSv with mean 
screening time of 11±7.3 minutes. The mean radiation exposure for MDCT angiography 
was 18.5±4 mSv with a mean scan time of 24 seconds (range 18-26). 
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5.5 DISCUSSION 
MDCT provides a highly specific means of detecting coronary artery bypass graft 
patency in a clinical setting. It is safe and abolishes the need for time consuming 
invasive coronary angiography which is associated with the small but significant risk of 
major complications. In contrast to invasive coronary angiography, it can be performed 
on a scheduled out-patient basis rather than requiring admission to a day case un.it. 
Computed tomography was first investigated as a possible method of determining 
patency of coronary artery bypass grafts in the early 1980s. Gunthaner et al(Guthaner, 
Brody et al. 1980) (1980) found that they were able to determine patency in 77.5% of left 
anterior descending (LAD) and right coronary artery (RCA) grafts and 40% of obtuse 
marginal (OM) grafts. Brundage et ai(Brundage, Lipton et al. 1980) published results 
that year showing 95% correlation between single slice CT and conventional 
angiographic detection of graft patency. With the advent of spiral and MDCT scanners, 
image quality has improved and, in line with this, interest in minimally invasive imaging 
techniques has grown. Since these first studies, further larger scale studies have been 
undertaken to assess the ability of CT to assess graft patency. Recently, Song and 
colleagues reported that MDCT imaging resulted in 99.4% specificity and 100% 
sensitivity, with 100% PPV and 80% NPV for detection of bypass graft patency.(Song, 
Ito et a!. 2005) This study, however, looked at patients (n=50) immediately post-
coronary artery bypass operation, who may be expected to have a high patency rate and 
no graft vasculopathy, thereby minimising any ambiguity caused by poor flow in 
chronically di seased grafts. Recent studies (n=25-65) looking specifically at graft 
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patency in study populations similar to the present, have reported sensitivities of 90-98% 
and specificities of 88-100% for detection of graft patency.(Engelmann, von Smekal et al. 
1997; Hoshi, Yamauchi et al. 2001; Marano, Storto et al. 2004) Consistent with our 
findings, detection of patency in vein grafts is more reliable than for internal mammary 
grafts.(Ha, Cho et al. 1999; Engelmann, Knez et al. 2000) 
We performed a pooled analysis of all available data from studies investigating CT as a 
non-invasive means of assessing coronary artery bypass grafts (Table 5.4).(Achenbach, 
Moshage et al. 1997; Engelmann, von Smekal et al. 1997; Engelmann, Knez et al. 2000; 
Ropers, Ulzheimer et al. 200 I; Burgstahler, Kuettner et al. 2003; Marano, Storto et al. 
2004; MartusceiJi, Romagnoli et aJ. 2004; Schlosser, Konorza et al. 2004; Chiurlia, 
Menozzi et al. 2005; Moore, Sampson et al. 2005) The paper by Nieman et al was not 
included in the analysis due to incomplete data on detection of graft occlusion by 
MDCT.(Nieman, Pattynama et al. 2003) The pooled data gave an overall sensitivity of 
96% and specificity of 99% (n=l498) for the detection of graft patency. As we bave 
observed, studies with a preponderance of vein grafts displayed more reliable patency 
rates than those with a large proportion of arterial grafts. Pooled analysis focussing on 
the breakdown of available data for IMAs (n=268) gave a sensitivity of 93%, specificity 
97%, PPV 99.5%, NPV 67% and an accuracy of 94%.(Engelmann, von Smekal et al. 
1997; Engelmann, Knez et aJ. 2000; Ko, Choi et aL 2003; Marano, Storto et al. 2004; 
Schlosser, Konorza et al. 2004) Pooled analysis of vein grafts in the same studies 
(n=399) gave a sensitivity of 97%, specificity 97%, PPV 99%, NPV 92% and an 
accuracy of 97%. 
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Table 5.4 Characteristics of studies assessing non-invasive imaging of coronary artery bypass grafts. 
Achenbach Engleman Engleman Ropers Koet Marano Schlosser Martuscelli Moore Cbiurlia Houslay Pooled 
et al et al et al etal al et al et al et al et al et al etal data 
Year of 1997 1997 2000 2001 2003 2004 2004 2004 2005 2005 2005 
publication 
Method Electron Spiral CT Spiral CT Spiral 4 slice 4 slice 16 slice 16 slice 4 slice 16 slice 16 slice 
beamCT CT MDC MDCT MDCT MDCT MDCT MDCT MDCT 
T 
No. of 25 49 24 65 39 57 51 96 50 52 so 
patients 
Mean age 64 61 61 67 60 65 65 62 69 63 66 
Sex(% 92 92 92 82 74 95 76 83% 76 87 86 
male) 
No. grafts 54 134 78 182 115 122 131 251 150 165 116 1498 
IMA I 42 20 20 40 95 40 85 38 46 35 462 
SVG 53 92 58 162 54 27 91 166 112 117 77 /009 
other 21 2 4 27 
%vein 
grafts 98% 69% 74% 89% 47% 22% 69% 66% 66% 70% 66% 
Mean graft 6.9 1.8 2.1 7.6 1.2 4.8 5.6 7 8 7.9 7.0 
age (yrs) 
Sensitivity 100% 92% 90.1% 97% 93% 93% 96% 100% 91 % 100% 93% 96% 
Specificity 100% 97% 100% 98% 99% 98% 95% 100% 100% 100% 100% 99% 
PPV 100% 99% 100% 97% 93% 93% 81 % 100% 100% 100% 100% 99% 
NPV 100% 78% 74% 98% 99% 98% 99% 100% 96% 100% 85% 95% 
Accuracy 100% 93% 92% 98% 98% 97% 95% 100% 97% 100% 95% 97% 
------ - ---- -··-··---····-·---- .. -- ... ·- - - .... 
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Computed tomography has many advantages over coronary angiography, including a 
lower complication rate, better ostial imaging and easy visualisation of vessels with 
anomalous origin and those where catheterisation has failed. MDCT in particular has 
the advantage of shorter breath hold times, faster gantry rotation and reduced slice 
thickness permitting better temporal and spatial resolution than previous CT scanners. 
MDCT is widely available in standard Radiology departments, unlike electron beam 
CT. 
The main limitation of CT imaging is the high radiation doses that are incurred. This 
may be of limited relevance in the population under question as it has been shown that 
the elderly are less susceptible to the lifetime risk of radiation exposure for any given 
dose.(Pierce, Shimizu et al. 1996) Nonetheless, the radiation dose is double that of 
conventional angiography. Whilst there are no national dose limits, the doses such as 
are incurred with CT angiography equate to more than eight times the annual natural 
background radiation exposure. 
Whilst CT angiography has shown promising results in the detection of bypass graft 
patency, a recent review article concluded that there is a lack of evidence-based data 
to support its use for evaluation of native vessels in patients presenting with chest pain 
(Schoenhagen 2007). CT angiography may be a helpful non-invasive imaging tool in 
evaluation of bypass grafts on a non-urgent outpatient basis, but clinical trials are 
needed before it can be used as a tool to evaluate native vessels in patients presenting 
acutely. 
98 
5.5.1 Study Limitations 
Image quality is highly dependent upon adequate heart rate control, with a great 
reduction in image quality in subjects with a heart rate of greater than 70 beats per 
minute, due to diastolic motion artefacts. While bypass grafts are less susceptible to 
cardiac motion artefacts than native vessels, this can stilJ be an issue (Fig. 5.2), in 
particular in posterior vessels, such as grafts to the circumflex artery. Not all of the 
patients who were recruited were on P-blockade therapy, which meant that image 
quality was in some cases suboptimal due to diastolic motion artefacts. In those 
patients who bad IMA grafts, the increased scan volume necessitated a long breath 
hold. In some patients, this led to a degree of respiratory artefacts towards the end of 
the scan time, which tended to coincide with the base of the heart and therefore the 
distal graft anastamoses. For this reason, we were also unable to assess the distal 
vessel 'run off' consistently. In future studies, this could be addressed by 
administering short acting P-blockers immediately prior to the scan. 
In clinical practice, it is helpful to have information as to the severity of stenosis in a 
vessel so as to plan revascularistion therapy. Due to motion artefact and artefact from 
surgical clips in some patients, we were unable to reliably assess stenosis severity. In 
addition, the raw data from the scans was lost, so we were unable to reconstruct the 
images at different points in the cardiac cycles, which may have been helpful in the 
assessment of each individual vessel. 
The use of 16 slice CT scanners has been superseded by newer 64 slice scanners, 
which have the advantage of narrow collimation and reduced scan times. Meyer et al 
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report reliable assessment of graft patency and stenoses in unselected populations 
using 64 slice scanners (Meyer, Martinoff et al. 2007). Furthermore, Zhang et al 
highlight improved rated of evaluation of proximal anastamosis, graft, distal 
anastamosis and run off vessel for 64 slice scanners in comparison to 16 slice CT 
(Zhang, Jin et al. 2006). 
Figure 5.2 Multiplanar reformat 
Multi planar reformatted image showing considerable motion artefact. The LIMA was 
judged to be occluded distally on MDCT (arrow). This was, however, patent on 
conventional coronary angiogram and is an example of how motion artefact can lead 
to a falsely occluded diagnosis at MDCT. 
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5.5.2 Conclusions 
In line with recent studies, we can confirm that MDCT is highly specific for the 
detection of bypass graft patency. It provides a safe, fast and cost effective means of 
imaging coronary artery bypass grafts but with the disadvantage of a high radiation 
dose. The introduction of new 64 slice MDCT scanners will result in further 
improved image quality which may enable non-invasive imaging to be the mainstay 
of assessment of graft patency in the future. 
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CHAPTER6 
NOVEL MAGNETIC RESONANCE IMAGING TECHNIQUES 
AND REMODELLING OF COMPLEX CAROTID 
ATHEROSCLEROSIS: 
A FEASIBILITY AND REPRODUCIBiliTY PILOT STUDY 
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6.1 BACKGROUND 
Cardiovascular disease is the commonest cause of premature death in Scotland and 
leads to substantial morbidity. Recent estimates put the prevalence of stroke in 
Scotland at 2.33 per 1000 (Alexander, Bugge et al. 2000). 
The principal initiating event in the pathogenesis of acute cardiovascular events is 
rupture or erosion of the atherosclerotic plaque (Davies 2000). This can lead to 
intravascular thrombus formation and the potential for acute vessel occlusion or 
thromboembolism. The resolution or progression of unstable plaques determines the 
immediate consequence of plaque rupture and the resultant clinical event experienced 
by the patient: a fifth of patients presenting with a transient ischaernic attack or minor 
stroke will have a subsequent major stroke (Flossmann and Rothwell 2003). Insights 
into the natural history of these acute plaque events are therefore fundamental to the 
understanding and treatment of acute cardiovascular disease. 
The examination of the carotid arteries of patients with recent cerebral ischaemia, 
provides an ideal opportunity to identify key features in acute plaque events. High 
resolution imaging of coronary arteries is currently only possible with invasive 
techniques, such as intravascular ultrasound (Newby, McLeod et al. 2001; McLeod, 
Newby et al. 2003). Moreover, ultrasound imaging of complex atherosclerotic 
plaques is limited by the poor resolution of in situ thrombus, potential distortion of 
geometry and the inability to image through calcified plaques. Non-invasive 
techniques, such as magnetic resonance imaging, hold promise, but applicability to 
the coronary circulation is limited by the relatively small calibre of the coronary 
vasculature and the movement artefact induced by continuous myocardial contraction. 
103 
Carotid arteries are more suitable for non-invasive imaging because of their greater 
calibre, superficial location and relatively static position. This vessel therefore lends 
itself more readily to the assessment of acute plaque events and subsequent 
remodelling. 
Magnetic resonance provides a means of non-invasive imaging without the need for 
ionising radiation and, with the use of dedicated surface coils, can produce high-
resolution images of carotid atherosclerotic plaques. Recent novel and exciting MR 
techniques can facilitate characterisation of complex atherosclerotic plaques. T1-, 
proton density and T2-weighted images and three-dimensional time-of-flight images 
can be used to identify complex plaque with surface defects, haemorrhage or 
thrombus (Cai, Hatsukami et al. 2002; Yuan, Zhang et al. 2002). The neovasculature 
and vasa vasorum are part of the inflammatory process in complex atherosclerotic 
plaques. Using the standard MR contrast agent gadolinium, it has been possible to 
image and quantify neovascularisation of carotid plaques in patients against 
subsequent histomorphometric analysis of carotid endarterectomy specimens (Kerwin, 
Hooker et al. 2003). 
The description of in vivo atherosclerotic plaque remodelling may have widespread 
implications for understanding the mechanisms and treatment of atherosclerotic 
disease including not only cerebrovascular disease but also coronary artery disease 




Fifteen patients with recent symptoms and signs of an acute transient ischaernic 
attack, amaurosis fugax or stroke were recruited from the acute neurovascular clinic at 
the Western General Hospital and the vascular surgical clinic at the Royal Infirmary 
of Edinburgh. Informed consent was obtained from all patients, and the study was 
approved by the regional ethics committee. All patients underwent careful clinical 
evaluation. Subsequent retention in the study was dictated by a Doppler ultrasound of 
the ipsilateral internal carotid artery which confirmed a >40% luminal stenosis (on 
ECST criteria), to account for their clinical symptoms and presentation. Exclusion 
criteria were women of child bearing potential, renal or hepatic failure, severe or 
significant co-morbidity, or if unable to tolerate the supine position. 
6.2.2 Magnetic Resonance Imaging 
In order to assess feasibility, each subject underwent the foilowing magnetic 
resonance imaging protocol. Subjects were placed in a head collar to reduce 
movement artefact. Carotid surface coils (bilateral four channel phased array) were 
applied to maximise resolution, and scanning was cardiac synchronised to minimise 
pulsation artefacts. A research dedicated magnetic resonance imaging scanner ( 1.5T 
GE Echospeed) performed a two dimensional time of flight (2D TOF) localiser view 
with a field of view (FOV) of 22 em. The carotid bifurcation was identified from the 
localiser sequence and subsequent sequences, based around the carotid bifurcation, 
included axial Tl DIR ' black blood' with a FOV of 14 em; proton density and T2 fast 
spin echo (FSE) with FOV of 13 em; and 3D TOP with FOV of 13 em before and 
after enhancement with an intravenous bolus of 0.1 mmollkg Dotarem® (Gadoterate 
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meglurnine, Guerbet S.A., Paris, France). For each sequence, this resulted in 9 slices, 
each 2mm thick, centred upon the carotid bifurcation of interest, thus giving coverage 
of 1.8 ern. In order to assess reproducibility, the imaging protocol was then repeated 
within 2 weeks of the first assessment. Measurements of plaque area and volume 
were then compared between the two sets of scans. 
In order to assess neovascularisation, four subjects underwent an initial DIR axial 
scan ( 11 slices, 2mm thick), followed by a fast spoiled gradient recalled echo 
sequence (FSPGR), with T -1 weighted images of the diseased carotid artery at 9 
locations, centred on the carotid bifurcation. Following the method of Kerwin et al, 
2003, each acquisition was repeated 10 times, with a repetition interval of 16 seconds. 
Coincident with the second image in the sequence, 0.1 mmol!kg of Dotarem® was 
injected at a rate of 2mL/s via a power injector. 
6.2.3 Quantification of Carotid MR images 
Through collaboration with the Image Analysis Core of the Wellcome Trust Clinical 
Research Facility, digital images were quantitatively assessed. Using existing 
software, the cross-sectional lumen and outer vessel wall boundaries were manually 
traced and cross-sectional areas calculated [Fig 6.1 ]. Plaque area was defined as the 
vessel area minus the lumen area. Overall plaque area and volume were measured 
with reference to the carotid bifurcation to ensure consistency and comparability of 
study segments. Variation in pixel intensities within the plaque was also assessed. 
All scans, prior to measurements, were set at the same intensity level (Level 1111, 
Width 222). A software package was then used to calculate the occurrences of 
different intensity levels within the plaque. Histograms of occurrences against 
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intensity were then generated, with the hypothesis that heterogeneous plaques would 
yield differing histograms to homogeneous plaques. 
Finally, neovascularisation was determined by the degree of gadolinium enhancement 
of the plaque. After the acquisition of the 9 locations around the carotid bifurcation, 
the area of the plaque on each location was manually traced as described above. 
These regions of interest (plaque areas) were then aligned for each of the J 1 time 
points and analysed for changes in signal intensity over time. 
6.2.4 Power Calculation and Statistical Analysis 
This was a preliminary study which aimed to establish the feasibi lity and 
reproducibility of novel magnetic resonance based techniques. An accurate estimate 
of statistical power was not possible. As a pilot study, the data generated will permit 
a formal power calculation to be made for potential future clinical trials. For the 
parametric and volumetric variables described above, reproducibility was assessed by 
the method of Bland and Altman,(Bland and Altman 1986) and a paired students t-test 
performed. The correlation between MRI and histological plaque grading, was 
assessed using the Kappa statistic. 
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6.3 RESULTS 
6.3.1 Feasibility and patient demographics 
A total of 15 patients were recruited. Eleven underwent the standard protocol 
described above. A further 4 patients (subjects 12-15) were recruited to undergo the 
neovascularisation protocol. The percentage of internal carotid artery stenosis on 
ultrasound, ranged from 48-90%. The time from symptoms to recruitment and initial 
scan was between 6 and 60 days. The time between flrst and second scans ranged 
from 1 to 7 days (table 6.1). 
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Table 6.1 Patient parameters 
Patient Affected Duplex% Symptoms Symptom Time 
side Stenosis to scan between 
time scans 
(days) (days) 
1 L 56 R arm weakness 6 1 
2 R 69 L arm weakness 14 7 
3 R 80 L arm weakness 30 7 
4 L 53 Expressive dysphasia 10 1 
5 L 90 Be urgers disease; 1 
RICA occluded 
6 R 48 R amaurosis fugax 23 1 
7 R 70 R amaurosis fugax 60 2 
8 L 70 R arm weakness 20 2 
9 R 70 R amaurosis fu gax 60 1 
10 R 85 L arm weakness 4 1 2 
11 R 70 L arm weakness 53 1 
12 L 80 R arm weakness, 48 1 
dysarthria 
13 L 80 Expressive dysphasia 46 1 
14 R 80 L arm weakness 14 1 
15 L 80 L amaurosis fugax 28 1 
6.3.2 Reproducibility 
Measurements of plaque area and volume were conducted on the two Tl weighted 
images before and after contrast agent Gadolinium. Although images were also 
obtained using T2 weighted, Proton Density and 3-D TOP scanning sequences, these 
were judged by 2 independent radiologists to be of unsatisfactory image quality for 
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the performance of structural measurements. It was thought that the longer duration 
of these sequences made them more sensitive to movement artefact. (Fig 6.2) 
Plaque area and volume measurements were generated for each slice. However, the 
mean measurement for all 9 slices was used for Bland Altman comparison as this was 
thought to be the most clinically relevant summary measurement. There were no 
significant differences between T 1 weighted measurements of plaque area or volume 
made on scan one or two (Figs. 6.3). Although there was no statistically significant 
difference in measurements when contrast agent was used, the confidence intervals 
were noted to be wider (Figs. 6.4) 
6.3.3 Plaque Characteristics 
Previous studies have used MRI to identify various components of carotid plaque by 
comparing MRI images around the carotid bifurcation, with matched histological 
sections. Cai et al produced a table of modified MRI classification for different types 
of atherosclerotic plaque (Table 2.3). These gradings were applied to each scan 
(Table 6.3). 
The occurrence of different intensity signals within the plaque was plotted as a 
histogram. Lipid gives a high signal on a T !-weighted scan, whereas fibrous tissue 
produces an intermediate signaL It was hypothesised that a complex plaque 
consisting of several components (lipid, haemorrhage, fibrous tissue), would produce 
a range of signal intensities, and hence a wider or bimodal histogram (Fig. 6.5). Fig. 
6.6 illustrates the relationship between the standard deviation of the intensity 
histogram for the internal carotid slice and overall MRI grading of the scan. 
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Table 6.3 
Modified AHA No. of patients 










Four patients underwent a neovascularisation sequence to assess the feasibility of 
previously reported methodology [Kerwin et al]. Fig. 6.7 demonstrates the change in 
intensity over time following intravenous injection of contrast agent gadolinium. The 
change in intensity signal in the plaque follows that of the jugular vein. Fig. 6.8 
depicts images of the common carotid artery and jugular vein at the same location, 
over progressive time points. Image 1 is just before contrast injection, and the jugular 
vein appears dark. Image 2 is following intravenous contrast and the vein appears 
bright. Over time, the dark rim of plaque in the carotid artery progressively brightens. 
In future, the aim is to confirm that the areas of changing signal intensity seen within 
the plaque on MRI correspond with regions of neovascu larisation by performing a 




Previous reports have claimed that it is feasible to image atherosclerotic plaque in 
carotid arteries using MRI (Yuan, Mitsumori et al. 2001). This project demonstrated 
that our centre was capable of employing these protocols in a similar fashion. 
Although the aim was to scan patients within 7-14 days of initial symptoms, the 
results demonstrate a time from symptoms to recruitment that varies between 6 and 60 
days. Patients were recruited from the acute neurovascular clinic; Lothian NHS 
guidelines state that patients referred for outpatient follow up and investigation 
following suspected TIA, should be seen within 2 weeks. However, despite this 
guideline, experience was that patients attended the clinic anywhere from 1-12 weeks 
after their initial presentation. The delay from symptoms to scan , was due to late 
referral to clinic. This time frame does however correlate with other studies which 
report scans conducted within 70-90 day of symptoms. 
Previous reports have used an MRI protocol of at least 4 contrast weightings (T 1-, 
PD-, and T2-weighted and 30 TOP) to image carotid plaque (Yuan, Mitsumori et al. 
2001). Although it has been suggested that the use of different contrast weightings 
can help classify different plaque components, the overall image quality varied greatly 
between different contrast weightings (Fig. 6.2). In this study, the Tl-DIR sequence 
yielded the best quality images which correlates with other studies that demonstrate 
lower variability between measurements performed on Tl weighted images compared 
with other sequences (Yuan, Beach et al. 1998). Although more information may be 
gleaned from a multi-weighted protocol, it was found that the inevitable increase in 
scanning time led to increased patient restlessness and a subsequent reduction in 
image quality due to movement artefact. In conclusion, although it may be feasible to 
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perform a 4 weightings sequence, it may result in the sacrifice of image accuracy, 
which is important when addressing small areas of interest. 
There was good reproducibility between scans performed at 2 separate time points. 
The mean difference in plaque area (scan 2 minus scan 1) was -0.56± 5.0 mm2 for Tl-
weighted scans pre-gadolinium (P=0.22) and -3.57±15.3 mm2 for Tl-weighted scans 
post-gadolinium (P=0.59) (Fig. 6.3). These results compare favourably with 
previously published reproducibility figures (Yuan, Beach et al. 1998). Although 
there was no statistically significant difference in measurements performed on scans 
post contrast injection (plaque area post gadolinium P=0.5, plaque volume post 
gadolinium P=0.5), the confidence intervals were noticeable wider (plaque area pre-
adolinium 95% CI -3.9 to 2.8; Plaque area post-gadolinium 95% CI -15 to 8.2). It is 
interesting that the use of contrast agent should lead to a greater variation in scan 
measurements. Bland Altman comparison of plaque measurements, made with and 
without contrast agent, demonstrates a tendency for the use of contrast to lead to 
overestimation in plaque size (Fig. 6.9). 
Another aim of thjs project was to familiarise our centre with the techniques of 
assessing plaque components. Certain features of plaque morphology (such as large 
lipid load and thin fibrous cap) are thought to increase the risk of plaque rupture and 
subsequent clinical sequelae. Previous studies have demonstrated the ability of MRI 
scanning to detect various morphological features of atherosclerotic plaques by the 
comparison of MRI images of carotid arteries with hlstological sections of the same 
artery following carotid endarterectomy. In this pilot study, a neuroradiologist graded 
the MRI scans using a previously reported criteria (Cai , Hatsukami et al. 2002). In 
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addition, a histogram of signal intensities within each plaque was plotted. Although 
the numbers were too small to achieve statistically significant differences, the trend is 
for a wider histogram with more complex plaques, i.e. a higher modified AHA 
classification. We hope to expand our study to include comparison with histological 
specimens in the future. 
The early results from neovascularisation sequences are encouraging. The initial 
graphs of changing signal intensity over time correspond with those produced by 
Kerwin et al (Kerwin, Hooker et al. 2003). One of the subjects failed to demonstrate 
increasing signal intensity after intravenous contrast followed by signal decay as the 
contrast cleared. This patient had not tolerated the procedure well and found it 
difficult to remain still, leading to poorer quality images, difficulty in identifying 
regions of interest on the scan, and subsequent discrepancies in matching areas 
imaged at different time points. We aim to develop a smoothing protocol for our 
images with which to eliminate movement artefact, as used by Kerwin et al. This 
should help overcome some of these problems. 
The main focus of this small pilot project was to assess the feasibility of conducting 
MR imaging of complex carotid plaques. It has allowed our centre to gain experience 
in this technique, and it has been demonstrated that this tool can be utilised in a 
reproducible fashion. This study provides essential pilot data that will allow aid in the 
planning of future projects. 
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6.4.1 Importance to NHS and possible implementation 
The long-term consequences of cerebrovascular disease require the provision of 
substantial health care resources. The identification of high-risk patients and the 
potential to develop treatment strategies to prevent progression to cerebral infarction 
are essential goals in the treatment of patients with symptomatic carotid artery 
disease. 
Clinically applicable non-invasive imaging modalities may provide a novel method of 
identifying those patients at greatest risk of developing acute stroke. Moreover, 
understanding the mechanisms of carotid plaque remodelling has the potential to 
develop novel therapeutic strategies to prevent progression to cerebral infarction and 
permanent disability. Finally, describing in vivo atherosclerotic plaque remodelling 
may have more widespread implications for understanding the mechanisms of 
generalised atherosclerotic disease including coronary artery disease and peripheral 
vascular disease. Magnetic resonance imaging may be capable of fulfilling these 
important roles. 
6.4.2 Conclusions 
We have shown that it is feasible to recruit patients with recent acute carotid plaque 
events for MRI scanning within an acceptable time frame. MR imaging of the carotid 
bifurcation using Tl weighted sequences has been used to provide statistically 
significant, reproducible information, similar to that reported in the literature. The 
tendency of contrast agent to increase the variability of measurements has been 
suggested, although this was not statistically significant. MRI features have been 
used to grade plaque morphology allowing correlation of plaque heterogeneity with 
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signal intensity heterogeneity as demonstrated by plotting histograms. Finally, we 
have been able to conduct a protocol for the demonstration of plaque 
neovascularisation, reproducing previously reported results. 
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Fig. 6.1 Lumen and vessel wall tracing 
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Fig 6.5 Histogram 
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Fig. 6.6 
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Fig. 6.8 Images of carotid artery plaque (yellow arrow), and jugular vein (green 
arrow); pre-contrast (1) and at subsequent time points following gadolinium injection 
(2-5). 
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Fig. 6.9 Bland Altman plot looking at measurement of plaque area in pre- versus 
post-contrast enhanced T l -weighted scans 
Bland-Aitman of Area PRE v POST: Difference vs average 
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SUMMARY AND FUTURE DIRECTIONS 
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In summarising the published data to date, along with the conclusions drawn from the 
body of research that comprises this MD thesis, it will be possible to comment upon 
the current status of non-interventional cardiac imaging and hypothesise as to where 
future research and innovations may lead. 
7.1 CORONARY ARTERY CALCIUM SCORING 
7 .1.1 Method of Quantification 
The correlation between coronary artery calcification and atherosclerotic disease has 
been documented since 1970 (Frink, Achor et al. 1970), but until more recently, there 
had been no specific method of quantifying the calcium load as detected by computed 
tomography. Agatston first described a scoring method in 1990 which has been the 
basis of the coronary calcium score since and upon which risk stratification has been 
based (Agatston, Janowitz et al. 1990). This scoring method is based upon the 
number, area and peak Hounsfield number of the calcific lesions identified, and is 
described in full in chapter 2. The accuracy and reproducibility of this measure, 
however, has been cast into doubt more recently, and alternative methods of 
quantification have been proposed and researched. Callister's group first proposed a 
volumetric score in 1998, and found it to have superior reproducibility when 
compared with the Agatston score (Callister, Cooil et al. 1998). This finding was 
repeated in 2002 by Kopp et al, who found that spiral MDCT with isotropic 
volumetric data improved reproducibility when compared with EBCT (Kopp, 
Ohnesorge et al. 2002). In the most recent and largest study to date, the Multi-Ethnic 
Study of Atherosclerosis (MESA) is a multicentre observational study of 6814 
initiated to investigate the prevalence, correlates and progression of subclinical 
cardiovascular disease. Baseline measures were taken which included CT coronary 
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calcium score. Agatston scores, calcium volumes and interpolated volume scores 
were calculated. Volume scores are calculated using the technique of isotropic 
interpolation, whereby the input data reconstructed and sampled at arbitrary cross 
sections between the original cross section to correspond with pixel size. The smaller 
size of the interpolated voxel allows a more accurate volume reconstruction of the 
calcium volume when compared to using the original slice thickness. The 
interpolated voxels are assigned a numeric value and, as with the Agatston method, 
only those greater than a Hounsfield Unit value of 130 are used to represent calcified 
plaque. An automated 3D reconstruction is acquired and a final score calculated 
which corresponds to the calcium volume load. The actual value in cubic millimetres 
is multiplied by 1000 to generate whole numbers and facilitate comparison with the 
traditional calcium score. The MESA study concluded that it is possible to obtain 
similar reproducibility for coronary calcium scoring using either EBCT or MDCT and 
that, for either scanner, the volume scoring method results in only a minimal 
improvement in interscan reproducibility when compared with the Agatston score 
(Detrano, Anderson et al. 2005). 
Overall, results from this study and other similar studies show that the calcium 
volume score is only slightly more reproducible when compared with the Agatston 
score (Callister, Cooil et al. 1998; Kopp, Ohnesorge et al . 2002; Ohnesorge, Flohr et 
al. 2002; Ulzheimer and Kalender 2003; Detrano, Anderson et al. 2005). 
7.1.2 Screening 
Much public funding is devoted to increasing the awareness of CHD and to 
identifying at risk populations in order to tackle primary prevention of the disease. A 
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widely use method of risk stratification is based on the Framingham study and takes 
into account age, total cholesterol, LDL cholesterol, systolic blood pressure, treatment 
for hypertension, and cigarette smoking. The Framingham risk score gives estimates 
for 'hard CHD' which includes myocardial infarction and coronary death. However, 
it cannot definitively give an answer as to the presence or absence of coronary 
disease. Coronary angiography can give information as to flow limiting lesions, but is 
an invasive procedure and identifies disease relatively late on. In addition, it is known 
that culprit lesions are often not flow limiting but are small ( <70%) so-called 
vulnerable plaques. Computed tomography is a relatively safe, fast and accessible 
mean of measuring the coronary calcium score as a surrogate for atherosclerotic 
disease. 
In order for a screening tool to serve its purpose, it must have a high negative 
predictive value. Shemesh et al have shown that, in asymptomatic patients, the 
absence of coronary calcification on CT is predictive of angiographically normal 
coronary arteries (Shemesh, Tenenbaum et al. 1996). Retrospective analyses have 
also suggested screening to be of benefit in asymptomatic patients with risk factors 
for CHD, although this appears to be less useful in individuals with fewer risk factors 
(Moser, O'Keefe et al. 2003). Until recently, there have been no large prospective 
studies to base recommendations upon. The Prospective Army Coronary Calcium 
(PACC) project, recruited 2000 healthy volunteers who were evaluated in terms of 
standard risk factors and CAC as measured by EBCT. The patients were followed up 
for a mean of three years in terms of subsequent coronary syndromes and sudden 
cardiac death. This study concludes that, in young asymptomatic men, coronary 
calcium scoring can provide a considerable, cost-effective, independent prognostic 
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indicator in predicting subsequent CHD event over and above current coronary risk 
factors. 
Having established that CAC correlates with the risk of CHD events, it is important to 
determine a scale of risk stratification in order for clinicians to act upon the results. A 
recent metanalysis of studies that have attempted to determine a risk stratification 
model has sought to assess the predictive value of the coronary calcium score after 
adjustment for standard CHD risk factors. The meta-analysis found a high degree of 
variation in the relative risk associated with different CAC scores, which appears to 
be due to many factors including method of quantification, trial conduct and the 
proportion of women recruited. It concluded that the coronary calcium score is an 
independent risk factor for CHD events and that even people with a low score (l-100) 
have around twice the risk of CHD events, with high scores (>400) having a risk of 
anywhere between 4.3- 17 times the risk (Pletcher, Tice et al. 2004). More recently, 
the St. Francis Heart Study recruited 1,005 participants with a baseline coronary 
calcium score above the 80'h percentile for age, who were randomised to treatment 
with atorvastatin, vitamin C and vitamin E (alpha-tocopherol) versus aspirin and 
matching placebo. The relationship of events with baseline calcium score and 
standard risk factors was assessed; it was found that the baseline score was higher in 
those who suffered subsequent CHD events and that there was a greater increase in 
coronary calcium score in those with subsequent CHD events. Change in coronary 
calcium score after adjustment for standard CHD variables, however, did not predict 
events (Arad, Goodman et al. 2005). The study did not publish data on relative risk 
associated with extent of CAC. Most recently, data from the MESA study 
demonstrated that CAC may be used in intermediate risk patients to identify those 
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who are at higher risk. However, it highlighted the considerable gender and ethnic 
variations which make setting specific cut off points for risk hard to set, thereby 
limiting its use as a screening test. The MESA study co-ordinators highlight the 
necessity for further evaluation of risk as well as potential cost benefit of using the 
presence of CAC as a screening tool in 'at-risk' patients (Lakoski, Cushman et al.). 
To summarise, it is clear that there is an association between the extent of CAC 
present and subsequent risk of CHD events. As yet however, there are no specific 
guidelines regarding relative risk and threshold for treatment. In 2000, the ACC/AHA 
Expert Consensus Document on electron-beam computed tomography for the 
diagnosis and prognosis of coronary artery disease concluded that the absence of CAC 
is a good negative prognostic indicator and that a positive test confirms the presence 
of atherosclerotic plaque. It also concludes that the greater the coronary calcium 
score, the greater the likelihood of prognostic disease; the relationship, however, is 
not linear and the true plaque burden may be underestimated (O'Rourke, Brundage et 
al. 2000). Since then, a number of larger scale studies have been commenced, 
including the St. Francis Heart Study and the PACC project which have recently been 
completed. Due for completion in the near future; the Risk Factors, Evaluation of 
Coronary Calcium and Lifestyle (RECALL) study, a population based prospective 
cohort study of the comparative value of risk stratification techniques for cardiac 
events. This study is powered to define the relative risk associated with the extent of 
coronary atherosclerosis as measured by the coronary calcium score. It aims to 
identi fy at risk groups who are most likely to benefit from primary prevention 
(Scbmermund, Mohlenkamp et al. 2002). 
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Currently, the coronary calcium score is looked upon as a new and very exciting 
method of detecting subclinical atherosclerosis and many centres offer this as a 
screening tool. However, there are as yet no specific evidence based guidelines as to 
the precise implications of the result, and no guidelines as how best to manage 
patients based upon their result. In the near future, with the completion of large 
population based studies, it is likely that we will have a better idea of the exact 
implications and usefulness of the coronary calcium score as a screening tool. 
7.1.3 Coronary Artery Calcification Progression and Risk of Subsequent 
Coronary Heart Disease Events 
The coronary calcium score has been used to track changes in the coronary 
atherosclerosis non-invasively. In 2000, Shemesh et al reported that EBCT can be 
used to track changes in coronary calcium score over time, as a useful way of tracking 
changes in coronary atherosclerosis (Shemesh, Apter et al. 2000). However, the study 
does not correlate this with clinical events and nor does it publish reproducibility data 
on their scoring method. Since then, an observational study of 817 patients who were 
referred for two sequential EBCT scans reported a greater increase in coronary 
calcium score in patients who had an MI compared to those who remained event free 
(Raggi, Cooil et al. 2003). The St. Francis Heart Study is the first large prospective 
study to draw conclusions on the significance of progression of CAC. It recruited 
l,005 subjects with a coronary calcium score of >80th percentile for age and gender 
and found a greater increase in baseline score in patients who subsequently 
experienced CHD events than in those who remained event free (Arad, Spadaro et al. 
2005). 
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Whilst there is a body of evidence to support progression of CAC as an indicator of 
subsequent risk of CHD events, there are no data to support the routine practice of 
serial CT scans to track disease progression. For example, how frequently would the 
scans require to be performed to notice a trend in change and, if it were an advocated 
method of follow up in such patients, would this be done for life? Furthermore, bow 
would this actually affect patient management? Would a perceived positive response 
to treatment result in cutting back in, or alteration to the treatment regimen? Not only 
would this place an enormous burden on healthcare funding and resources, but there is 
a significant radiation dose incurred with repeated CT. Such exposure to ionising 
radiation is impossible to justify without a clear evidence basis supporting the 
investigation in question, nor indeed as to how to interpret the results and base 
treatment upon thereafter. 
7.1.4 Coronary Artery Calcification as a Measure of Response to Therapy 
The recent publication of the St. Francis Heart Study and the Beyond Endorsed lipid 
Lowering with EBT Scanning (BELLES) study has concluded many years of 
controversy over the role of serial coronary calcium scoring in monitoring disease 
response to therapy. Callister's group, in 1998, conducted a retrospective study of 
patients who had undergone two screening EBCT scans more than a year apart, and 
found that the extent of progression, stabilisation or regression was directly related to 
HMG CoA reductase inhibitors (Callister, Raggi et al. 1998). Budoff et al in 2000 
also documented a reduction in progression related to statin therapy in a retrospective 
observational study (Budoff, Lane et al. 2000). In 2002, Achenbach et al conducted 
an uncontrolled prospective evaluation study which indicated that cerivastatin reduces 
progression of CAC (Achenbach, Ropers et al. 2002). In contrast to these findings, in 
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2003, Hecht et al published results of a non blinded comparative observation study of 
more versus less aggressive lipid-lowering therapy. They found that, whilst there was 
a significantly greater reduction in LDL-cholesterollevels, there was no change in the 
degree of CAC (Hecht and Harman 2003). 
The striking feature of the studies described is that none is a prospective, blinded, 
placebo-controlled study and therefore the results have to be interpreted with extreme 
caution. Many patients have undergone serial CT scans to monitor therapy on the 
basis of the above studies which support the modality as a means of detecting 
response to therapy. A more definitive answer has been provided with the completion 
of tbe BELLES and St. Francis Heart Study. 
BELLES randomised 615 hyperlipidaemic postmenopausal women to intensive 
versus moderate lipid lowering therapy (atorvastatin 80 mg and pravastin 40 mg 
respectively). Patients underwent EBCT at baseline and after one year of treatment. 
The study found no less progression of CAC in the aggressive lipid-lowering arm 
despite superior LDL-cholesterol lowering (Raggi, Davidson et al. 2005). The study 
is limited, however, by the relatively short period of follow-up and the absence of a 
placebo group. The St. Francis Heart Study randomised 1,005 patients with a 
coronary calcium score greater than the 801h percentile for age either to treatment with 
atorvastatin 20 mg, vitamin C 1 g daily and vitamin E 1,000 U daily or to matched 
placebo for a mean treatment period of 4.3 years. They found that, whilst there was a 
significant reduction in LDL-cholesterol and also in CHD events in the treatment 
group, this did not affect the progression of CAC as measured by EBCT (Arad, 
Spadaro et al. 2005). In contrast to the BELLES study, the St. Francis Heart Study 
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was placebo controlled and participants followed up for over 4 years. This study is 
pivotal in defining the role of coronary calcium scoring in current clinical practice. 
When the ACC/ AHA Expert Consensus Document on electron-beam computed 
tomography for the diagnosis and prognosis of coronary artery disease was published 
in 2000, it identified grey areas, or deficiencies in the then current body of evidence. 
First of all, it concluded that the literature showed that EBCT, whilst having a high 
sensitivity, bad a low specificity and overall predictive accuracy of around 70%. It 
was felt that EBCT did not provide a superior alternative to existing non-invasive 
diagnostic methods such as SPECT imaging. The document stated that, in order to be 
of value, the test should confer an added prognostic benefit over and above readily 
available methods such as the Framingham risk model, described earlier. 
Furthermore, at the time, the published literature was not able to define specific 
cohorts who would benefit from EBCT and stressed that the screening modality 
should not be readily available to the public without specific referral from a physician. 
Another area which was highlighted was the inter-observer and inter-test variability. 
The document concluded that further properly designed outcomes research was 
needed, along with studies assessing the role of serial EBCT scanning in progression 
or regression of CHD. 
Since 2000, the studies published and summarised above, namely the St. Francis 
Heart Study, BELLES, MESA and PACC go a long way to providing answers to the 
above questions. Due for completion in the near future, RECALL should provide the 
additional evidence with which to formulate guidelines as to who is likely to benefit 
from CAC screening. 
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7.1.5 Summary of Thesis Research Conclusions 
We have confirmed that, despite marked reductions in serum LDL cholesterol and C-
reactive protein concentrations, atorvastatin 80 mg daily did not halt the progression, 
or induce regression, of coronary artery calcification in patients with calcific aortic 
stenosis. Consistent with recent trials of asymptomatic individuals (Arad, Spadaro et 
al. 2005; Raggi, Davidson et al. 2005), our findings are in marked contrast to previous 
observational studies and suggest that the potential beneficial effects on coronary 
artery calcification have been over estimated. We have demonstrated good 
reproducibility of coronary artery calcification scores in patients with scores of 
greater than 100 AU. [n contrast to the BELLES and St. Francis Heart Study, our 
cohort was selected upon the basis of the presence of calcific aortic stenosis, and was 
treated only with statio, rather than statins and vitamin E. However, the fact that we 
reached the same conclusions further supports the fact that, whatever the population, 
statins do not reduce CAC. 
With the constant development of newer and more sophisticated technology, in 
particular MDCT, the accuracy and reproducibility of the modality continues to 
improve. This will enable the coronary calcium score to be used more predictably for 
defining risk of future cardiac events. With increasing experience and use of the 
imaging modality, if differences in the coronary calcium score over time are proven to 
result in different event rates then it is likely that serial measurements will provide a 
powerful predictive tool enabling treatment to be tailored to each individual. We 
conclude that intensive lipid lowering therapy does not halt the progression, or induce 
regression, of coronary artery calcification. Although coronary artery calcium scores 
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correlate well with the presence of atherosclerosis and predict future coronary risk, 
our findings confirm that there is no role for monitoring progression of coronary 
artery calcification in order to assess the response to lipid lowering therapy. 
7.2 COMPUTED TOMOGRAPHY ANGIOGRAPHY 
7.2.1 Technology 
The advantage that invasive coronary angiography, the current gold standard method 
of imaging coronary vessels, holds over computed tomography, is its excellent 
temporal resolution (<!Oms) This is of importance due to the fact that imaging of the 
heart must be performed during fast and complex cyclical motion with considerable 
beat to beat variation. The temporal resolution of even the most technologically 
advanced CT scanner is significantly poorer than this, at between 50-300 ms. It is 
possible to minimise motion artefacts by acquiring images during late diastole when 
there is little cardiac motion. 
The disadvantage of coronary angiography is that it is an invasive procedure which is 
associated with the risk of stroke, myocardial infarction and death as well as the risk 
of local complications at the puncture site. Furthermore, while it provides precise 
informat ion on lumen diameter and the presence and site of stenosis, invasive 
coronary angiography provides no information on the state of the vessel wall. For 
example, it is known that luminal stenosis is a relatively late feature in the natural 
history of atherosclerosis, with positive arterial remodelling acting to compensate for 
the development of atherosclerotic plaque. Thus, a normal vessel lumen size at 
angiography may grossly underestimate the extent of disease. Intravascular 
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ultrasound has the ability to provide information as to vessel wall properties and 
atherosclerotic plaque volume but, again, is an invasive procedure. 
7.2.2 CT Angiography- Native Vessels 
In carefully selected patients, CT angiography is becoming a safe, feasible and 
accurate means of detecting native coronary vessel patency and the presence of 
significant stenoses. A recent meta-analysis reviewed the literature from 1950 until 
March 2005 and drew conclusions as to the sensitivity and specificity of contrast-. 
enhanced MDCT for the detection of coronary artery disease (Stein, Beemath et al. 
2006). To summarise, they found that there was at least 95% sensitivity for the 
detection of significant stenoses, namely stenoses of ~50%, with 4-, 16-, and 64-slice 
MDCT. As would be expected, the specificity increased with the number of 
detectors, as did the sensitivity for significant stenoses in evaluable segments and the 
overall number of evaluable segments. They found that the published data reported a 
higher sensitivity for stenoses in proximal and mid segments as opposed to distal 
segments. When evaluating lesions in named arteries, the sensitivity was higher for 
the left main stem and left anterior descending arteries than for the circumflex and 
right coronary arteries, although the differences were small with the latest 64-slice 
scanner. A summary of the literature is shown in Table 1. 
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Table 7.1. Detection of significant stenosis (~50%) according to coronary artery 
segment 
Year No. of No. of Sensitivity Specificity 
published detector patients (%) (%) 
rows 
Neiman et a/( Nieman, 01 4 53 82 93 
Rensing et al. 2002) 
Nieman et a/( Nieman, 01 4 31 81 97 
Oudkerk et al. 2001) 
Becker( Becker, Knez et 02 4 28 81 90 
aJ. 2002) 
Kopp(Kopp, Schroeder et 02 4 102 86 96 
a t. 2002) 
Leber et al(Leber, Knez et 03 4 91 82 96 
al. 2003) 
Gaudio et a/( Gaudio, 05 4 6 1 77 91 
Mirabelli et at. 2005) 
Dirksen(Dirksen, Jukema 05 4 25 95 91 
et a t. 2005) 
Maruyama(Maruyama, 04 8 25 90 99 
Yoshizumi et al. 2004) 
Matsuo(Herzog, Ay et at. 04 8 25 75 96 
2001) 
Neiman(Nieman, 02 16 58 95 86 
Cademartiri et al. 2002) 
Mollet(Mollet, 04 16 127 92 95 
Cademartiri et al. 2004) 
Kuettner( Kuettner, 04 16 58 72 97 
Trabold et al. 2004) 
Leta(Leta, Carreras et at. 04 16 31 75 91 
2004) 
Hoffman U(Hoffmann, 04 16 33 63 96 
Moselewski et at. 2004) 
Martuscelli(Martuscelli, 04 16 61 89 98 
Romagnoli et al. 2004) 
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Paul(Paul, Ohanessian et 04 16 29 86 99 
aL 2004) 
Candemartiri(Cademartiri, 05 16 40 96 96 
Runza et al.) 
Schuijf(Schuijf, Bax et aJ. 05 16 45 98 97 
2005) 
Mollet(Mollet, 05 16 5 1 95 98 
Cademartiri et al. 2005) 
Kuettner(Kuettner, Beck 05 16 72 82 98 
et al. 2005) 
Hoffman 05 16 102 95 98 
MHK(Hoffmann, Shi et 
aJ. 2005) 
Leschka(Leschka, 05 64 67 94 97 
Alkadhi et al. 2005) 
As suggested above, MDCT angiography has its limitations. The image quality is 
degraded by artefacts in patients with irregular hear rhythms and breathing during the 
scan. Large calcific deposits in atherosclerotic plaque cause beam hardening and 
partial volume artefacts which can completely obscure the cross section of the vessel 
and prevent assessment of patency. Similarly, metal objects such as stents, surgical 
clips and sternal wires can interfere with image quality. The right coronary artery is 
the most rapidly moving, especially in its mid portion, and motion artefacts are most 
frequently seen there. The motion pattern of the left anterior descending and 
circumflex arteries are related to left ventricular contraction, whereas the right 
coronary artery moves synchronously with the right side of the heart. This causes 
problems with reconstruction algorithms. The optimal phase for viewing the left 
sided ruteries may be suboptimal to view the right coronary artery. However, with the 
improved temporal resolution provided by 64-slice CT, and ever improving 
141 
reconstruction algorithms, these factors which degrade the image quality can be 
minimised. Whilst with older 4-slice CT scanners, only 78% of segments could be 
evaluated, 91% could be evaluated with 16-slice and all segments with 64 slice (Stein, 
Beemath et al. 2006). Recent data show that the 64 slice CT provides high diagnostic 
accuracy in assessing coronary artery stenoses and, importantly, when compared to 
older generation scanners, has ability to assess a greater proportion of coronary artery 
segments (Leschka, Alkadhi et al. 2005). With the advent of 128-slice scanners, this 
accuracy would be expected to improve further and has the potential of providing an 
accurate and non-invasive means of assessing coronary artery stenoses. 
7.2.3 CT Angiography- Coronary Artery Bypass Grafts 
Even in its early stages, computed tomography bas been investigated as a means of 
non-invasively determining the patency of coronary artery bypass grafts. Coronary 
bypass grafts are more easily imaged than native vessels due to their large calibre (in 
the case of venous grafts) and reduced susceptibility to cardiac motion artefacts. 
Sensitivities and specificities of greater than 90% were achieved even with single 
slice spiral CT (Engelmann, von Smekal et al. 1997). The data regarding graft 
patency has been discussed extensively in Chapter 5; Table 4, Chapter 5 provides 
pooled data regarding the sensitivity and specificity of MDCT in determining graft 
patency in the literature. Data on the accuracy of CT for the detection and grading of 
haemodynamically significant stenoses, however, is relatively lacking and tend to be 
based on small study population size. Nonetheless, CT angiography with 16- slice CT 
allows accurate assessment of venous and arterial grafts in patients who have no 
contra-indications to MDCT angiography. 
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7 .2.4 Summary Of Thesis Research Conclusions 
MDCT provides a highly specific means of detecting coronary artery bypass graft 
patency ln a clinical setting. It is safe and abolishes the need for time consuming 
invasive coronary angiography which is associated with the small but significant risk 
of major complications. In contrast to invasive coronary angiography, it can be 
performed on a scheduled out-patient basis rather than requiring admission to a day 
case unit. In line with recent studies, we can confirm that MDCT is highly specific 
for the detection of bypass graft patency. It provides a safe, fast and cost effective 
means of imaging coronary artery bypass grafts but with the disadvantage of a high 
radiation dose. The introduction of 64 slice CT scanners will result in further 
improved image quality which may enable non-invasive imaging to be the mainstay 
of assessment of graft patency in the future. 
7.3 MAGNETIC RESONANCE ANGIOGRAPHY 
MR angiography with intravenous contrast has become a routine method of assessing 
the degree of stenosis of the carotid, aorta, renal and peripheral arteries. MRA 
techniques have also been proposed for assessment of the coronary vasculature. I 
propose to focus on the literature examining the use of MRA in the carotid vessels. 
7.3.1 Lumen Imaging 
The carotid artery is primarily imaged using 20 time of flight (TOF), 3D TOF and 
contrast enhanced MRA. 20 tends to offer the best edge definition but is susceptible 
to artefact from patient movement. Three dimensional techniques, however, give 
better spatial resolution and create fewer artefacts. The use of gadolinium as a 
contrast agent acts to increase the signal of blood in relation to surrounding tissue, and 
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reduces the time required for image acquisition (10-20 seconds vs. around 10 mins 
with standard TOF acquisition). However, in comparison to TOF, contrast-enhanced 
MRA (CE-MRA) has been shown to increase the demonstrated degree of stenosis by 
an average of 20-30% (Townsend, Saloner et al. 2003). In order to determine stenosis 
severity, therefore, only axial TOF images should be used. 
Various papers have investigated the correlation between stenosis severity as assessed 
by MRA versus ultrasound and digital subtraction angiography (DSA). Patel et al 
found that MRA correlated well with ultrasound, with 3D TOF outperforming 20 in 
terms of sensitivity and specificity when single imaging modalities were compared to 
angiography (Patel, Kuntz et al. 1995). Anderson et al reported MRA and DSA to be 
similar in their assessment of carotid bifurcation stenosis, with 2D and 3D TOF MRA 
comparing more closely with DSA than ultrasound (Anderson, Saloner et al. 1992). 
Both authors concluded that DSA is only required to clarify stenosis severity when 
ultrasound and MRA are discordant. This method is safer, as it avoids the risks 
associated with an invasive procedure, and is also more cost effective (Anderson, 
Saloner et al. 1992). 
7.3.2 Plaque Imaging 
The three most important aspects of plaque morphology in atherosclerosis imaging 
are (i) plaque size, thickness, eccentricity and distribution along the vascular bed; (ii) 
plaque composition with respect to lipid/necrotic core, fibrous matrix, haemorrhage 
and calcification and (iii) plaque inflammation. The various properties of these 
components have been characterised in terms of their signal intensity characteristics 
on T 1-, T2-, and intermediate-weighted images and have been described in Chapter l. 
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In recent years, various centres have investigated the validity of these measures. 
Misumori et al compared measurements of vessel wall volume, maximum wall area 
and minimum lumen area determined using in vivo black blood MRI assessment and 
ex vivo in patients undergoing carotid endarterectomy. Results indicate that in vivo 
black blood MRI can provide accurate measurements on different aspects of carotid 
atherosclerotic plaque burden (Mitsumori, Hatsukami et al. 2003). The technique has 
also been found to be reproducible (Kang, Polissar et aJ. 2000). In terms of plaque 
composition, MR has been used to identify unstable plaque (Hatsukami, Ross et al. 
2000; Mjtsumori, Hatsukami et al. 2003; Trivedi, Jet al. 2004), soft plaque (necrotic 
core or haemorrhage) (Yuan, Mitsumori et al. 2001) and intraplaque haemorrhage 
(Chu, Kampschulte et al. 2004) with rugh levels of agreement with rustological 
fjndings. This information has enabled classification of human carotid atherosclerotic 
plaques according to American Heart Association (AHA) classifications. A recent 
study of 60 patients who underwent MR scanning prior to carotid endarterectomy 
showed good agreement between MR imaging and AHA classification (Cai, 
Hatsukami et al. 2002). 
7.3.3 Monitoring of Therapy 
Imaging in cEnical trials is required to be non- or minimally invasive, to provide 
quantitative information on plaque morphology, tissue components and inflammatory 
activity of lesions at various stages and be fully validated against a pathological gold 
standard. In adilition, they should allow repeated study of the same vascular bed, 
using reliable landmarks in a multicentre environment where small changes can be 
identified consistently. Validation stuilies to support such requirements are 
summarised above and provide the basis for several past and ongoing trials. Zhao et 
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al have demonstrated a reduction in plaque lipid volume, as assessed by MRI, with 
prolonged lipid lowering therapy (Zhao, Yuan et al. 2001). Corti et al demonstrated 
that maintained lipid-lowering therapy is associated with regression of atherosclerotic 
lesions and is associated with sustained vascular remodelling (Corti, Fuster et al. 
2002). Whilst these studies were based in a single centre, promising results as to the 
feasibility of mulicentre trials are available. Chu et al acquired quantitative 
measurement of lumen, wall, outer wall, lipid-rich/necrotic core and calcification with 
excellent correlation across four time points at five different clinical sites (Chu, 
Kampschulte et al. 2004). ORION (Outcome of Rosuvastatin treatment on carotid 
artery atheroma: a magnetic resonance Imaging ObservatioN) is an ongoing study to 
assess the effect of lipid lowering on progression of atherosclerosis using 
The study has reported that MRI can 
and the distribution of lesion in 
multicontrast, high-resolution MRI. 
reproducibly determine lesion types 
hypercholesterolaernic patients with moderate carotid artery stenosis (Chu, Hatsukarni 
et al. 2004). 
7 .3.4 Summary of thesis research conclusions 
We have shown that it is feasible to recruit patients with recent acute carotid plaque 
events for MRI scanning within an acceptable time frame. MR imaging of the carotid 
bifurcation using T 1 weighted sequences has been used to provide statistically 
significant, reproducible information, similar to that reported in the literature. The 
tendency of contrast agent to increase the variability of measurements has been 
suggested, although this was not statistically significant. MRI features have been 
used to grade plaque morphology allowing correlation of plaque heterogeneity with 
signal intensity heterogeneity as demonstrated by plotting histograms. Finally, we 
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have been able to conduct a protocol for the demonstration of plaque 
neovascularisation, reproducing previously reported results. 
7.4 FUTURE DIRECTIONS 
7.4.1 Coronary Artery Calcium Scoring 
As discussed above, data published as part of this body of research along with 
international data has shown that there is no rationale for the use of serial coronary 
calcium scoring in order to monitor response to lipid-lowering therapy. However, 
there is evidence to support its use as a diagnostic tool to aid in the treatment and 
prevention of cardiovascular diseases, as its presence is indicative of the presence of 
underlying atheromatous disease. Screening of high risk populations, or those for 
whom conventional first line investigations have been equivocal, is a real possibility 
in the near future. 
7.4.2 Therapy Targeted At Lowering Coronary Artery Calcification 
Whilst lipid-lowering has proven benefits in the treatment of atherosclerosis, it has no 
effect on the coronary calcium score. Progression of CAC is associated with an 
increase in cardiovascular events (Raggi, Cooil et al. 2003; Arad, Spadaro et al. 2005) 
and therefore it would follow that therapy aimed at reducing CAC would be 
beneficial. The pathogenesis of atherosclerosis has been discussed in Chapter 1, but 
is still not fu lly understood. Recent reports have suggested an infectious aetiology, 
with infectious blood nanobacteria thought to have a role in triggering the process 
(Puskas, Tiszlavicz et al. 2005). Maniscalco et al found that combined EDT A and 
tetracycline therapy resu lted in significant regression of calcified coronary plaque 
volume of, on average 14%. This was associated with a decrease in anginal 
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symptoms, although it was not powered to detect a change in event rate. This study, 
whilst small numbers and a relatively short treatment period (four months), is 
promising; larger placebo controlled studies are required to assess possible future 
therapy. 
Previous studies have demonstrated an association between a deletion polymorphism 
of the angiotensin converting enzyme (ACE) gene and an increased risk of coronary 
artery disease (Nakai, Itoh et al. 1994) and myocardial infarction (Cambien, Poirier et 
al. 1992). Furthermore, the incidence and extent of CAC is directly related to the 
polymorphism; the ACE DD (homozygous for the ACE deletion) genotype is an 
independent determinant of CAC (Pfohl, Athanasiadis et al. 1998). Recently, a 
retrospective study, which assessed the rate of change of aortic valve calcification as 
measured by EBCT, observed a significant reduction in the rate of aortic valve 
calcium accumulation in patients who were receiving ACE-inhibitor therapy (O'Brien, 
Probstfield et al. 2005). A link between pathogenesis of aortic valve calcification and 
arterial atherosclerotic plaque has been suggested (Mohler ill 2000) and, therefore, it 
may be extrapolated that ACE-inhibitors may act also to reduce the extent of CAC. 
7.4.3 Plaque Imaging 
Whilst CAC score can predict those at risk of cardiovascular disease/events, it gives 
no information on plaque morphology. MR techniques have been described which 
give information as to plaque volume, composition and fibrous cap using standard 
sequences with and without the addition of standard MR contrast agents. However, a 
contrast agent used to identify macrophages in patients with lymph node metastases 
was noted incidentally to produce signals in aortic plaques (Schmitz, Taupitz et al. 
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2001). This contrast agent consists of ultrasmall superparamagnetic particles of iron 
oxide (USPIOs), is available for clinical use (Sinerem®, Guerbet Laboratories), and is 
a potential method of looking at monocyte and macrophage activity in atherosclerotic 
plaques; a fundamentally important process in atherogenesis and plaque remodeling. 
Animal studies suggest that this is a promising technique to observe macrophage 
traffic in hyperlipidaemic model (Ruehm, Corot et al. 2001). In patients given 
Sinerem 24 hours before carotid endartectomy (Kooi, Cappendijk et al. 2003), 
histology has confirmed localisation of USPIOs to the atherosclerotic plaque. 
Recently, the novel contrast agent has been used to identify plaque inflammation in 
patients with symptomatic carotid stenosis by demonstrating accumulation of USPIO 
in macrophages within the plaques(Tang, Howarth et al. 2006; Trivedi, Mallawarachi 
et al. 2006). Currently, this contrast agent is not yet licenced for use in MRA, but 
phase m clinical trials are underway. This would provide yet more information as to 
plaque vulnerability and help target therapeutic agents. 
7 .4.4 MR Spectroscopy 
MR spectroscopy (MRS) is used to characterise biochemical components in tissues of 
interest by using frequency information, instead of to provide spatial or positional 
information as in MRI, to identify different chemical compounds. Initial data 
published in 1990 showed that it could be used to distinguish mobile lipids and 
differential between normal triglyceride content and cholesterol-enriched lipids in 
animal models (Booth, Honey et al. 1990). More recently, image-guided MRS has 
been shown accurately to identify cholesterol ester in discrete pre-selected regions of 
atherosclerotic plaque as small as 1 mm3 in ex vivo studies (Ruberg, Viereck et al. 
2006). 
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Magnetic resonance spectroscopy can also be used to estimate tissue temperature. In 
ischaemic stroke, our centre has recently shown that the temperature in an acute lesion 
is higher than normal brain (Figure 7.1). This may reflect a pro-inflammatory 
response, and be linked to the pyrexia observed in those patients who have a worse 
outcome. Magnetic resonance spectroscopy has the potential to be developed to 
assess local tissue temperature changes in association with ischaemia or inflammation 
both in the brain and other tissues including atherosclerotic plaques. This would be 
complemented by tracking inflammatory cells using USPIO and SPIO imaging 
techniques as described above. 
Figure 7.1 
Ischaernic stroke imaged by magnetic resonance diffusion weighted image (left) and 
spectroscopy (right). The hottest areas (reds and yellows) are in the infarct itself and in 
the immediate surrounding tissue- the ischaernic penumbra. 
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7.5 Conclusion 
We have established, according to the original aims set out m Chapter 1, that 
computed tomography can measure coronary calcium score in a reproducible manner, 
and that lipid-lowering has no effect on the progression of coronary calcification. We 
have established that MDCT can be used reliably to predict graft patency in patients 
who have undergone coronary artery bypass grafting. Finally, we have pilot data to 
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